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ABSTRACT
Functional foods may have a role to play in either preventing or treating obesity. Both
preventive and treatment studies were carried out in this project. The preventive study
was carried out in rats fed a high-fat diet (HFD) adding low dose (LD), medium dose
(MD) and high dose (HD) of Oats (O) and Shiitake mushroom (M) containing 2g/kg,
6g/kg and 18g/kg beta-glucans (LD-O, MD-O, HD-O and LD-M, MD-M, HD-M)
compared to HFD control group for 6 weeks. The treatment study was carried out in
obese rats induced by HFD for 8 weeks followed by adding Shiitake mushroom powder
containing 6g/kg, 12g/kg and 18g/kg beta-glucans in the diets as low, medium and high
doses.
The interesting findings of this study overall are, the diets with a Shiitake mushroom
appeared to be stronger lowering plasma lipid than the diets with enriched oats which
include their beneficial effect in lowering weight.
The results showed that both oats and Shiitake mushroom enriched diets had
significantly higher faecal fat exclusion compared to the HFD; while Shiitake
mushroom enriched diet had lower levels of plasma triacylglycerol (TAG) level, total
fat mass deposition and body weight gain compared to oat enriched diets. The HD-M
group had the highest amount of faecal fat exclusion among all groups. In comparison
to HFD, the HD-M diet prevented the increase in plasma TAG, fat deposition and body
fat index and also resulted in decreased energy efficiency. Negative correlations were
found between the amount of Shiitake mushroom supplementation and body weight
gain, plasma TAG, and total fat masses.
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This study demonstrated that lowering of plasma TAG and prevention of BWG using a
Shiitake mushroom enriched diet was also possibly influenced by eritadenine content in
Shiitake mushroom. We found that the HD-M group significantly increased liver
weight per 100 g body weight and liver TAG compared with rats fed the LD-M and
MD-M diets but it was not significantly different from rats fed the HFD. The rats in the
HD-M group showed the highest incidence of hepatic ballooning, resulting from
decreased ratio of liver phosphatidylcholine (PC) to phosphatidylethanolamine (PE),
which can probably be attributed to eritadenine contained in Shiitake mushrooms. This
decrease ratio of PC to PE has been associated with increase membrane permeability
and hence promoting influx of lipoproteins into the liver.

Unlike the prevention study, the treatment study showed no significant effects. The
Shiitake mushroom did not accomplish the dietary treatment effect on existing obesity.

In conclusion, this study revealed that a Shiitake mushroom enriched diet was more
powerful in preventing high-fat diet induced obesity than oats enriched diet through the
increased fat faecal exclusion; however, increased TAG in liver can be an issue when
ingesting a high dose of Shiitake mushroom. But, the addition of choline chloride to the
diet may help to prevent this side effect. This warrants further investigation. The
treatment study showed that shiitake mushroom enriched diet was not sufficient to
reverse obesity. This information may provide significant information assisting the use
of Shiitake mushrooms and oats as functional foods for the prevention of obesity.
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CHAPTER 1.
1.1

LITERATURE REVIEW

Obesity

Obesity is a global health problem. The World Health Organisation (WHO) predicts that
by 2015, approximately 2.3 billion adults will be overweight and more than 700 million
will be obese (WHO 2006). This problem occurs in developed and developing
countries. In Australia, the prevalence of obesity has more than doubled in the past
twenty years (Cameron 2003) and in Indonesia the prevalence of central obesity has
reached 19.1% adults (Indonesia, 2008).
The pathophysiology of obesity is still under significant investigation. What we do
know is that the development of obesity is associated with the influence of genetic and
environmental factors and activity (Lin, Thomas et al. 2000; Pi-Sunyer 2002). Each of
these three factors can found a major investigation and requires significant effort.
Within the environmental factors, diet plays an important role contributing to the
pathophysiology of obesity development. This will be the focus of my study. In the diet,
some foods are obesogenic but others are not.
A disproportionate energy intake to the energy expended will induce fat mass
deposition called adipose tissue (Albu and Pi-Sunyer 1998). For example, saturated fat
promotes positive energy balance and leads to increased fat deposition, particularly in
the visceral organs. As the fat deposits increase, this promotes adipocyte stress and
proliferation. All this pathology will contribute to the development of cardiovascular
diseases such as arthrosclerosis, coronary heart disease and liver disease. On the other
hand, other food can be very beneficial in terms of reducing fat deposition and
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prevention of obesity, for example, oats and mushrooms added into our diet. In the
following, I will review their effects on obesity.
The classification of obesity from the Expert Panel on the Identification, evaluation and
treatment of overweight and obesity in adults is shown in Table 1.1.
Table 1.1 Classification of BMI
Classification of BMI

Body mass index (BMI) (Kg/m2)

Overweight

25 – 29.9

Obesity (Class 1)

30 – 34.9

Obesity (Class 2)

35 – 39.9

Extreme obesity (Class 3)

>40

Source : (NHLBI Obesity Education Initiative October 2000)
1.2

Implications of obesity

The main implication of obesity is not the increase of fat per se, but its consequences for
other systems. In recent years, obesity has been widely reported to induce metabolic
syndrome, cardiovascular disease, diabetes mellitus and cancer (Hotamisligil 2006;
Huang and Chen 2009; Chen , Katsifis et al. 2011).
In obesity, the fat mass is not only known as the storage organ of excessive energy, but
also has been recognized as an active endocrine organ, playing an important role in the
regulation of whole body energy homeostasis, insulin sensitivity, and lipid/carbohydrate
metabolism through the secretion of several hormones (Albu and Pi-Sunyer 1998;
Clarke and Judd 2008).
The term dyslipidaemia refers to a pathological disorder that encompasses abnormalities
of lipoprotein transport and high blood lipid levels (Thompson 1990). Hyperlipidaemia
is often associated with obesity and the incidence of cardiovascular diseases. The
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increase in total plasma cholesterol is correlated with body weight although less
strongly than the increase in plasma triglycerides (TAG) (Thompson 1990). The survey
conducted by the National Health and Nutrition Examination Survey (NHANES) on the
relationship of obesity to blood lipids reflects a common dyslipidaemia pattern in
obesity such as hypertriglyceridaemia, hypercholesterolemia and lower HDLcholesterol (HDL-C). The increase in plasma TAG will provide fatty acid for
adipogenesis (Novelli, Diniz et al. 2007; Voshol, Rensen et al. 2009). Adipogenesis will
increase adipose tissue that produces paracrine and autocrine inflammatory signals (Tilg
and Moschen 2006; Clarke and Judd 2008). The increase in adipose tissue in obesity
decreases adiponectin production and thus induces decreased insulin sensitivity
(Yatagai, Nagasaka et al. 2003; Yamamoto, Hirose et al. 2004), metabolic syndrome
(Matsushita, Yatsuya et al. 2006), dyslipidaemia (Matsushita, Yatsuya et al. 2006) and
cardiovascular disease (Kumada, Kihara et al. 2003; Pischon, Girman et al. 2004).
Accordingly, dyslipidaemia was not only the cause of obesity but also the risk factor of
obesity. Prevention of dyslipidaemia, such as lowering plasma TAG levels, will
decrease fat pad accumulation. Lowering fat mass deposition will inhibit metabolic
disorders including dyslipidaemia. The link between obesity and dyslipidaemia can be
seen in Figure 1.1

Dian Handayani

3

Figure 1.1 A high-fat diet is one trigger in the formation of a continuous circle of
dyslipidaemia and obesity.

The prevalence of obesity could be decreased by preventing obesity and/or treating
obesity. Obesity is a chronic disease that raises the risk factor or comorbidities of
obesity such as insulin resistance, dyslipidaemia, cardiovascular disease and for some
cancers. The increasing risk factors are not easily treated and successful treatment
requires a lifelong effort (Barlow and Dietz 1998; NHLBI Obesity Education Initiative
October 2000). The increasing risk factor of obesity will have an impact in the form of
rising medical spending per capita that accounts for a +3.4%, +2.3%

and +1.9%

increase related to dyslipidaemia, hypertension and heart disease respectively compared
to non-obese people (Thorpe, Florence et al. 2004) .
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1.3

Management of obesity

Recommendations from the experts including physicians, nurses and dieticians propose
that treatment of obesity should be started early and supported by the whole family. A
long term dietary program for maintaining and reducing body weight is recommended
and should be monitored and evaluated continuously (Barlow and Dietz 1998).
Therefore, this long term diet therapy requires such high levels of commitment that
sometimes it commonly results in patients dropping out, unwilling to continue the long
term dietary treatment (Hardy 2000).
Given these issues, prevention of obesity will be of considerable importance in avoiding
the rise of obesity as a chronic disease. Prevention is required not only to avert increase
of BWG per se, but also to prevent the rise of other risk factors from obesity such as
dyslipidaemia, fat mass deposition that can result in increased blood pressure, and blood
glucose.
The World Health Organisations prediction of 700 million obese people in 2015 (WHO
2006) means that effective treatment strategies are required to assist in decreasing the
prevalence of obesity.
Obesity is associated with frequent consumption of high energy density foods such as
fast foods (Jekanowski, Binkley et al. 2001; Prentice and Jebb 2003). In the USA, the
consumption of fast food increased from approximately 29% in 1980 to 38% in 2000
and this increase was primarily due to an increase in the total demand of food eaten
away from home (Stewart, Blisard et al. 2004). The energy density of fast food is
usually higher than the energy density from a normal diet, for example, the energy
density of typical fast food is almost 2 fold higher compared to the average British diet
and 2.5 fold higher compared to the African diet (Prentice and Jebb 2003). The
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increased fat consumption clearly plays a part in inducing overweight and obesity cases.
In an animal study it was reported that long term consumption of high-fat/high-energy
food resulted in an adverse effect of insulin and ghrelin expression on plasma and
organs (Wang, Ni et al. 2012). On this view, prevention of obesity may be assisted by
avoiding consumption of a high fat diet or high energy intake diet.

Interestingly, in parallel with the increase in obesity and increased fast food
consumption, is an increasing community awareness of the use of functional foods to
solve health problems (Hardy 2000). A significant amount of functional food has been
offered in the community for prevention and treatment of obesity, however the scientific
evidence that functional food can assist in weight loss is limited (Clifton 2008). It has
been reported that lowering plasma triacylglycerol (TAG) levels will be efficient in
combating BWG as an increased plasma TAG level was significantly correlated with
increase in body mass index and fat pad masses in rats (Novelli, Diniz et al. 2007).
Beta-glucan is well documented as lowering plasma lipids in human (Behall, Scholfield
et al. 1997; Kerckhoffs, Hornstra et al. 2003; Reyna-Villasmil, Bermu´ dez-Pirela et al.
2007; Maki, Beiseigel et al. 2010) and animal (Bae, Kim et al. 2009; Andersson,
Svedberga et al. 2010) studies.

The combination of the trend to consume a high fat diet, a reluctance to adhere to long
term dietary treatment and the increased demand for functional foods, has encouraged
the study of functional foods as a dietary intervention for weight loss while retaining the
ability to consume a high-fat diet which needs further investigation.
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1.4

Functional food for obesity

The term “functional food” emerged for the first time in Japan in 1980. Functional food
as part of medicinal treatment has been preferred in order to anticipate increasing health
costs (Arai 1996). Several definitions of the term functional food exist, including one
from The European Commission, Concerted Action on Functional Food Science in
Europe, which regards a food as functional, „if it is satisfactorily demonstrated to affect
beneficially one or more target functions in the body, beyond adequate nutritional
effects, in a way that is relevant to either an improved state of health and well-being
and/or reduction of risk of disease‟ (Diplock, Aggett et al. 1999). Another term is from
the Bureau of Nutritional Sciences, of the Food Directorate of Health Canada. Food will
be classified as functional food if it is “Similar in appearance to conventional food,
consumed as part of the usual diet, with demonstrated physiological benefits, and/or to
reduce the risk of chronic disease beyond basic nutritional functions” (Health Canada
2002).
The functional food industry also expanded following the increased public awareness of
the link between diet and health. On the global functional food market in 2001, the
values of worldwide functional foods were higher compared to the value of the
supplement market (Invest Australia 2004).
Functional food has been grouped into conventional food, modified food and
synthesized food ingredients (Henry 2010). Moreover, food will be grouped as
functional food if it can demonstrate beneficial effects when it is retained in food form
and not formed into pills or capsules (Diplock, Aggett et al. 1999). Oats and Shiitake
mushrooms have been grouped as functional foods. The significant difference
comparing beta-glucan and crude powder is that beta glucan is one of the most
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important components of the crude powder, which has a potent biological function in
increasing satiety (Juvonen, Purhonen et al. 2009), reducing cholesterol and fat
deposition (Behall, Scholfield et al. 1997; Delaney, Nicolosi et al. 2003; Kerckhoffs,
Hornstra et al. 2003; Xu, HaiYan et al. 2008; Kim, Kang et al. 2010). The crude powder
of oats and mushroom contains many other ingredients such as vitamins, minerals and
fatty acids (Crea Nutrition). In addition, the crude powder of Shiitake mushroom also
contains chitin, eritadenine and ergothioneine (Mattila, Konko et al. 2001; Dikeman,
Bauer et al. 2005; Enman, Rova et al. 2007).

This study used oat and Shiitake

mushroom powders, which contain high concentrations of beta-glucans (oat 22% and
Shiitake 30%). Many other components of oats and Shiitake mushroom can also be
active ingredients involved in lowering blood cholesterol, TG and body weight in an
animal model, such as polyphenol and linolenic acid. Therefore, the results reported in
this study do not exclude other bioactive ingredients from oats and Shiitake mushroom.
A specific dose of oat and mushroom powder will be added into rat food to understand
the effectiveness of an oat or mushroom enriched diet to prevent and treat obesity.
Even though oats and mushrooms had positive effects in improving dyslipidaemia, there
are no comprehensive studies on their role in the prevention and treatment of obesity,
including their effect on plasma lipid, fat pad accumulation, body weight gain (BWG)
and on identification of the underlying mechanisms in obesity prevention and treatment.
1.5

Oats, dyslipidaemia and obesity

Consumption of oats has been reported to have numerous health benefits. Welldocumented is its plasma cholesterol lowering effect (Behall, Scholfield et al. 1997;
Delaney, Nicolosi et al. 2003; Kerckhoffs, Hornstra et al. 2003; Karmally, Montez et al.
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2005; Queenan, Stewart et al. 2007; Reyna-Villasmil, Bermu´ dez-Pirela et al. 2007;
Maki, Beiseigel et al. 2010). The component of oats thought to be responsible for the
lowering of cholesterol is its soluble, non-starch polysaccharide, beta-glucan. Oat betaglucan consists of linear unbranched β-(14)-D-glucopyranose units, which are
separated every 2-3 units by a single β-(13)-linked glucose unit (Volman, Ramakers
et al. 2008).
The evidence has shown that oat beta-glucan has the capacity to improve dyslipidaemia
by various mechanisms. For example, oats as a soluble fibre are commonly known to
increase the viscosity and affect the structural properties of meals and viscosity of the
digestive system (Andersson, Svedberga et al. 2010). The soluble fibre content and high
viscosity of beta-glucan causes delay in gastric emptying and increases the feeling of
satiety (Jenkins, Jenkins et al. 2002; Reyna-Villasmil, Bermu´ dez-Pirela et al. 2007;
Juvonen, Purhonen et al. 2009). Indirectly, high viscosity will influence the degree of
absorption of nutrients including fat (Delaney, Nicolosi et al. 2003). A reduction in fat
absorption lowers plasma lipid levels and influences the cholesterol supply in the liver
because of the lower source of chylomicron remnants (Durrington 2007). Oat betaglucan was also reported to increase significantly cholesterol exclusion in the faeces
(Delaney, Nicolosi et al. 2003) and bile acid excretion (Lia, Halmans et al. 1995) and
also decreases bile acid re-absorption (Beer, Arrigoni et al. 1995), all of which explains
the cholesterol lowering effect.
Even though the United States Food and Drug Administration (FDA) concluded that
daily consumption of 3g of oat beta-glucan decreases plasma cholesterol by 5-8%,
results from clinical studies have been inconsistent, with some showing no significant
improvement in plasma lipid (Lia, Halmans et al. 1995; Lovegrove, Clohessy et al.
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2000; Kerckhoffs, Hornstra et al. 2003; Maki, Davidson et al. 2003) and others showing
a positive effect (Kerckhoffs, Hornstra et al. 2003; Karmally, Montez et al. 2005;
Queenan, Stewart et al. 2007; Reyna-Villasmil, Bermu´ dez-Pirela et al. 2007). This
inconsistency may be affected by different methods of processing and preparation of the
oats (Anttila, Sontag-Strohm et al. 2004). Kerckhoffs, Hornstra et al (2003) compared
the physiological effect of oat beta-glucan baked in bread and cookies with 6g oat betaglucan added into a drink; the results showed that only oat beta-glucan in the drink gave
a significant reduction in cholesterol levels. However, this mode of administration
appears not to be an important factor because other studies from Lovegrove, Clohessy et
al (2000) reported additional 20g oat concentrates with 3g beta-glucan in low fat milk
or yoghurt showed no effect on plasma lipid.
The molecular weight (MW) of beta-glucan was reported to influence food viscosity in
the intestine (Kerckhoffs, Hornstra et al. 2003). Food viscosity has been known to have
beneficial effects in improving dyslipidaemia via several pathways, including inhibiting
fat absorption and increasing faecal fat exclusion. However, the relationship between
the MW of beta-glucan and its functional effects are still debatable. For example, Tosh,
Brummer et al. (2008) reported that to achieve functional effects of beta-glucan, the
MW should be > 1,000,000 dalton. A study from Bae, Lee et al (2009) reported that the
MW of beta-glucan was not always positively correlated with weight gain and lipid
profile on mice fed an oat beta-glucan enriched diet. Bae et al showed that a lower MW
of beta-glucan (370,000 dalton) seems to have a greater effect on reducing cholesterol
and TAG than a high MW (1,450,000 dalton) in mice fed 20% oats (wt:wt). However, a
high MW of oat beta-glucan has been reported better for reducing BWG (Bae, Kim et
al. 2009). Other clinical studies in hypercholesterolemic subjects showed that
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consumption of beta-glucan with a MW of 1,200,00 dalton significantly decreased
plasma low density lipoprotein (Braaten, Wood et al. 1994). Again, a study from
Kerckhoffs, Hornstra et al (2003) reported that a clinical study with

oat dietary

treatment with a MW < 1,200,000 dalton showed no significant plasma lipid lowering
effect when oat was added into bread or biscuits. The studies showed that the effects of
oat beta-glucan on reducing plasma lipid have had various results and the functional
effects were dependent on the food matrix and molecular weight.
In summary, the effect of oats on body weight also has not, to my knowledge,
demonstrated consistent results in clinical studies. One clinical study showed oats did
not decrease body weight though it was given concurrently with a hypo-caloric diet in
healthy subjects for a six week dietary intervention (Saltzman, Moriguti et al. 2001);
and another clinical study showed oat decreased body weight when it was given
concurrently with a low fat diet and followed with moderate physical activity (ReynaVillasmil, Bermu´ dez-Pirela et al. 2007). Therefore, studying the effect of an oat
enriched diet in rats fed a HFD in preventing obesity will provide important information
for the design of dietary intervention about whether an oat enriched diet on an HFD
achieved a significant effect in lowering plasma lipid, fat mass accumulation and
ultimately prevention of obesity.
1.6

Mushrooms, dyslipidaemia and obesity

Mushrooms are an ancient food consumed by many people in the world. Mushroom
consumption has recently increased, for example data from the United States showed
that it increased by 21% in one decade from 1991; that is approximately 1.7 kg (on a
fresh-weight basis) per capita in 2001 (Lucier, Allshouse et al. 2003). Again, the data
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from the Australian Bureau of Statistics, 2006, showed that mushrooms are the second
most valuable fresh vegetable crop in Australia, after potatoes (Gordon 2007). The
reason for increased mushroom consumption is the belief that their active components
may have beneficial effects on a variety of biological systems (Mattila, Suonpää et al.
2000).
Mushrooms have been identified as containing a range of nutrients such as Vitamin B,
Vitamin D, potassium, copper, magnesium, selenium, zinc and dietary fibre, in
particular chitin, and beta-glucan (Manzi, Aguzzi et al. 2001; Wu, Pae et al. 2007; Ren,
Giuo et al. 2008). It has also been reported that mushrooms are quite high in protein
(19-35%, including all the essential amino acids) as well as low in fat. Mushrooms
contain relatively large amounts of carbohydrate and fibre, ranging from 51 to 88% and
from 4 to 20% (dry weight) respectively for the major cultivated mushrooms (Mattila,
Suonpää et al. 2000).
Mushrooms have been revealed to provide many sound medical benefits. The primary
bioactive components of mushrooms are grouped into polysaccharides (homo glucan
and hetero glucan), other polysaccharides (chitin, chitosan), glycoprotein groups,
eritadenine and L-ergothioneine (Ahren, Mansson et al. 1997; Dikeman, Bauer et al.
2005; Enman, Rova et al. 2007; Regula and Siwulski 2007).
Previous research demonstrated that mushrooms improve dyslipidaemia in an animal
model as a mushroom powder (various) enriched diet (Kabir and Kimura 1989; Kubo
and Nanba 1996; Kubo and Nanba 1997; Cheung 1998; Fukushima, Nakano et al. 2000;
Fukushima, Ohashi et al. 2001; Talpur, Echard et al. 2002; Chandra, Smith et al. 2011),
polysaccharide extracted from mushrooms such as beta-glucan (Kim, Kim et al. 2005;
Vetvicka and Vetvickova 2007; Xu, HaiYan et al. 2008; Kim, Kang et al. 2010) and
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other biological components extracted from mushrooms such as chitin, chitosan (Koide
1998; Neyrinck, Bindels et al. 2009) and eritadenine (Takashima, Izumi et al. 1973;
Takashima, Sato et al. 1974; Sugiyama, Akachi et al. 1995; Sugiyama, Yamakawa et al.
1997; Sugiyama, Yamakawaa et al. 1997; Shimada, Morita et al. 2003). In one human
study, Oyster mushrooms were also reported to improve dyslipidaemia especially in
plasma TAG (Schneider, Kressel et al. 2011).
Beta-glucan in mushrooms is recognized as a substantial component for treating several
diseases, for example increasing the immune response (Chen and Seviour 2007;
Vetvicka and Vetvickova 2007; Wu, Pae et al. 2007) and lowering hyperlipidaemia
(Cheung 1998; Chen and Seviour 2007). In the context of lowering plasma lipid,
Cheung (Cheung 1998) explained that mushroom beta-glucan has the potential to lower
plasma TC and TAG due to increased viscosity.
Again, mushroom dietary fibre was also reported as the most likely candidate for
lowering plasma lipid; the mechanisms are fermentation of dietary fibre that produced
short chain fatty acids (Jeong, Jeong et al. 2010), increasing faecal fat exclusion
(Fukushima, Ohashi et al. 2001) and increasing bile acid excretion (Kubo and Nanba
1997). The main structure of beta-glucan in mushrooms is 13 β-linked
glucopyranosyl with some 1,6 β-linked branches (Volman, Ramakers et al. 2008). The β
(13) is reported as a linkage that makes the molecule flexible, and contributes to its
high water binding, solubility and viscosity (Anttila, Sontag-Strohm et al. 2004). The β
(13) linkage was also reported to have stable gel strength through multiple freezethaw cycles (Lehtovaara and Gu 2011). These studies revealed that mushroom dietary
fibre, beta-glucan, has the potential to lower plasma lipid.
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Mushrooms have different levels of beta-glucan content that is dependent on the
mushroom variety.
Shiitake mushrooms showed the 3rd highest beta-glucan content behind the other
commercial mushroom samples (Table 1.2).
Table 1.2 Percentage of total glucan, alpha-glucan and beta-glucan contents of a range
of commercial mushroom samples.

Sample

Glucan content (dry weight basis)
Total
AlphaBetaGlucan
glucan
glucan

Dried black fungus

49

0.2

48

Dried Maitake mushroom

43

0.3

42

Shiitake clear spring

45

6

39

Shiitake (Zhejian baihuagu; Shenzhen Dashan

30

2

30

White button mushroom *)

19

4

5

Marel Caps

29

8

21

Belotus edulis

7

4

24

Morchela conica

27

19

8

Porcini Mushroom

38

5

29

Dried Trompettes mushroom

16

1

15

Melange forestier mixture

29

2

28

Foodstuff Co.LTD) *)

Source :(Megazyme 2008)
*) from local store in Australia - analysed by Megazyme kit in “Nutrition lab”
University of Wollongong
Another biological property of mushrooms that has beneficial effects in lowering
hyperlipidaemia is eritadenine. Eritadenine can be found in edible mushrooms such as
Shiitake mushrooms (Enman, Rova et al. 2007) and in Agaricus bisporus mushrooms to
a lesser extent (Saito, Yasumoto et al. 1975). Eritadenine was reported to decrease
plasma TAG and TC and was also 10 times more effective in lowering plasma lipid than
clofibrate (Takashima, Izumi et al. 1973; Takashima, Sato et al. 1974). Normally, liver
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fat that comes from non-esterified fatty acid and de novo lipogenesis will be released to
the circulation as very low density lipoprotein (VLDL) (Thompson 1990; Durrington
2007). Studies have shown that eritadenine lowers plasma lipid in the circulation by
depressing the secretion of TAG-rich lipoprotein, increases uptake of plasma
lipoprotein, and inhibits apoprotein assembly (Sugiyama, Akachi et al. 1995; Sugiyama,
Yamakawaa et al. 1997; Shimada, Morita et al. 2003). One potential mechanism of
eritadenine in lowering dyslipidaemia is by decreasing the concentration of
phosphatidylcholine (PC) and increasing the concentration of phosphatidylethanolamine
(PE) in the liver (Sugiyama, Akachi et al. 1995; Walkey, Yu et al. 1998). PC was
recently recognized as an important phospholipid for lipoprotein assembly and secretion
from the liver (Cole, Vance et al. 2011). The liver synthesized PC from the CDPcholine pathway and the phosphatidylethanolamine N-methylation (PEMT) pathway
(Watkins, Zhu et al. 2003). The CDP-choline pathway supplied the largest PC source in
the liver (Vance, Li et al. 2007), and this pathway was dependent on the presence of
choline in the diet (Watkins, Zhu et al. 2003). Therefore, additional eritadenine in an
diet with insufficient choline will lower the PC concentration in the liver (Sugiyama,
Akachi et al. 1995). In addition, eritadenine was reported to decrease S-adenocylhomocysteine hydrolyse (Votruba, Morand et al. 1985) which resulted in increased
levels of S-adenocyl-homocysteine (AdoHcy) (Schanche, Schanche et al. 1984). The
increased levels of S-adenocyl-homocysteine will decrease the ratio of Sadenocylmethionine (AdoMet) to S-adenocyl-homocysteine. The decreasing of this
ratio resulted in decreased PC production from the PEMT pathway (Sugiyama, Akachi
et al. 1995). Other studies also reported that the balance of PC and PE concentration in
the liver was needed for the normal assembly between TAG and Apo-B as well as the

Dian Handayani

15

secretion of VLDL from the liver (Li, Agellon et al. 2006; Vance, Li et al. 2007). The
presence of TAG in the liver normally resulted in VLDL secretion from the liver after it
was packaged with Apo B (Durrington 2007). Accordingly, the homeostasis of PC and
PE concentration were important factors for packaging and releasing of VLDL. As TAG
were a major component of VLDL, the addition of eritadenine in the diet without
additional choline will decrease PC which in turn will result in the liver synthesising
and secreting less VLDL which in turn results in decreased plasma TAG levels
(Takashima, Sato et al. 1974; Sugiyama, Akachi et al. 1995).
In brief, the mechanism of eritadenine from Shiitake mushrooms can be seen from
Figure 1.2
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Figure 1.2 Pathway of eritadenine involved in phosphatidylcholine (PC) biosynthesis
for normal release of VLDL. The black line is the normal mechanism to produce the PC
from the CDP-choline pathway and the CDP ethanolamine pathway. The red dashed
line shows the effect of eritadenine from a Shiitake enriched diet which contains
insufficient choline.

Chandra et all (2011) recently reported that a Shiitake mushroom enriched diet induced
hepatic steatosis on mice fed a normal diet with 5% Shiitake mushroom added
(Christopher, Traore et al. 2010; Chandra, Smith et al. 2011)

that contained

approximately 193 mg eritadenine/kg diet (Enman, Rova et al. 2007).
An eritadenine enriched diet without additional choline in the diet will induce hepatic
steatosis (Sugiyama, Akachi et al. 1995). Choline is also known as part of the Vitamin
B complex (Taminco).
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Due to the eritadenine promoted side effect of hepatosteatosis, whether a high
concentration of Shiitake mushroom enriched diet will prevent obesity, but promote
liver lipid accumulation in rats fed HFD, needs further investigation. The diet of this
current study contains choline chloride from additional Vitamins (~14 g/kg of food)
(MP Biomedical, Ohio, US) and existing vitamin B from Shiitake mushrooms (2.3
g/100 g mushroom powder), in total around ~ 41 mg Vit B/kg diet, however it was not
known whether this choline from a semi-synthetic vitamin and the existing natural
vitamin B from mushrooms would inhibit fatty liver.
Chitin is a long-chain polymer of N-acetylglucosamine, a derivative of glucose
(Dikeman, Bauer et al. 2005). Chitin is a component of the cell walls of fungi, the
exoskeletons of arthropods, such as crustaceans (e.g. crabs, lobsters and shrimps) and
insects, including ants, beetles and butterflies, the radula of mollusks and the beaks of
cephalopods, including squid and octopuses (Nwe and Stevens 2002; Biomaterials.
2008).
The chitin in mushrooms makes up 15% of total dietary fibre (TDF) which is much less
than the beta-glucan content which ranges from approximately 65% to 85%. Chitin in
mushrooms is reflected as glucosamine while the beta-glucan content in mushrooms is
reflected as glucose (Cheung 1996).
Mushrooms

reported

to

contain

chitin

are

Shiitake

(Lentinus

edodes),

Schizosaccharomyces pombe, Candida albicans, Saccaromices cereviceae, Muxor
rouxii, Phycomyces blakesleeanus, Caprinus cinereus, Neurospora crasca, Mucor spp,
and Mortierella isabelina (Suntornsuk, Pochanavanich et al. 2002).
Chitin will lower plasma lipid after it is converted into chitosan (Koide 1998; Neyrinck,
Bindels et al. 2009). The fermentation technology in mushrooms and deacetylation of
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chitin with sodium hydroxide will produce chitosan (Crestini, Kovac et al. 1996; Ravi
Kumar 2000; Teng, Khor et al. 2001). As the complex mechanism to produce chitin into
chitosan (Aranaz, Mengíbar et al. 2009), no study found that conversion of chitin to
chitosan occurs in the mammalian digestive system. Usually, studies using mushroom
chitosan and crustacean cell chitosan have been provided in a commercial preparation
(Han, Kimura et al. 1999; Neyrinck, Bindels et al. 2009). It was suggested that
mushroom chitin per se will not lower plasma lipid.
In summary, there are various types of mushrooms containing different amounts of
beta-glucan. In general, mushrooms have beneficial effects for dyslipidaemia and
obesity. In the following section, I will focus on a review of Shiitake mushrooms for
treating obesity.

1.6.1

Shiitake Mushroom

The Shiitake mushroom contains beta-glucan and is also reported to lower plasma lipid.
World production of Shiitake mushrooms is increasing as is the biological component
of Shiitake mushrooms, eritadenine. Eritadenine is valuable in lowering plasma lipid
which possibly promotes the beneficial effect of Shitake mushrooms in prevention and
treatment of obesity.
Research has shown that the beta-glucan content of Shiitake mushrooms is higher than
that of oats (Megazyme 2008; Beck, Tosh et al. 2009). Lentinan is known as beta
glucan from Shiitake mushrooms that contain (13)-β-D- glucan as the main structure
and have a (1 6)-glucosyl side group (Zhang, Li et al. 2011). Shiitake mushroom has
more than 30% beta-glucan (Megazyme 2008) compared to oats which contain 22%
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(Crea Nutrition). Shiitake mushrooms have also been reported to have a high
eritadenine content (Takashima, Sato et al. 1974; Enman, Rova et al. 2007). Shiitake
mushrooms had the highest eritadenine content among other edible mushrooms such as
Agaricus bisporus, Shimeji (Lyophyllum aggregatum), Jelly–ear (Auricularia auriculajudae), Enokitake (Flammulina velutipes), and Nameko mushrooms (Pholiota nameko)
(Saito, Yasumoto et al. 1975). Eritadenine levels in Shiitake mushrooms were
approximately 3 – 6 mg/g dry weight mushroom and was dependent on the variety of
mushroom and the extraction method (Enman, Rova et al. 2007). Several studies also
reported that eritadenine extracted from Shiitake mushrooms was essential for lowering
plasma lipid (Takashima, Izumi et al. 1973; Sugiyama, Akachi et al. 1995; Sugiyama,
Yamakawa et al. 1997; Shimada, Morita et al. 2003). The effect of Shiitake mushroom
eritadenine has mostly been analysed in extraction form or purified eritadenine from
Shiitake mushrooms (Takashima, Sato et al. 1974; Sugiyama, Akachi et al. 1995;
Shimada, Morita et al. 2003). Only a limited study was reported to use Shiitake
mushrooms and to analyse the effect of eritadenine from Shiitake mushrooms (Chandra,
Smith et al. 2011). Therefore, this study will provide the first information about the
effect of a Shiitake mushroom enriched diet in preventing obesity in rats fed HFD with
consideration of the effect of the beta-glucan and eritadenine content.

1.7

Using rats fed HFD as animal model for obesity

There are several ethical and pragmatic constraints associated with using human
subjects, while animal experiments are reproducible and robust. Another consideration
is that at the end of the dietary trial, blood and tissue (such as liver and fat) can be
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collected for biochemical analyses. Using an animal model induced by HFD is better
to reflect the physiology of the obese human than using a genetically obese animal
model such as ob/ob mice (Van Heek, Compton et al. 1997), because to date, only a
rare mutation in the genes encoding leptin or the leptin receptor has been detected in
humans. This indicates that the majority of human obesity cannot be attributed to a
defect in leptin or its receptor. Moreover, to mimic obesity in humans, rats had been
induced by a high fat diet. Male Wistar rats were used in this study because the
menstrual cycle of female rats can affect the results based on the time of biological
measurements. Also, most data in the literature of this kind are from male rats; this
means that my data can be compared with theirs. However, female data must be
studied in the future.
On a HFD, diet fat has been added as the largest percentage (amount) compared to other
macro nutrients such as carbohydrate and protein. The high fat diet will increase the
energy density of food and it is easier to induce positive energy balance resulting in
obesity. Normally, fat content in the normal rat diet is 30% from total calories
(Nutrition., Nutrition. et al. 1995). Studies in developing obese rats using higher fat
content compared to the normal diet have shown the range to be approximately 42%
(Buettner, Parhofer et al. 2006) up to 75% (Xu, HaiYan et al. 2008).
Additional coconut oil in the rat diet was reported to produce a higher increase in
plasma TAG compared to the addition of lard in the diet. It was reported that plasma
TAG will increase 133% and 75% when coconut and lard respectively are added
(Buettner, Parhofer et al. 2006). The increase in plasma TAG in rats provided fatty acid
for adipogenesis (Novelli, Diniz et al. 2007). As reported by Thompson (Thompson
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1990), the increase in plasma TAG was more closely related to obesity compared to a
diet high in cholesterol.
High sucrose in a rat diet was reported to induce de novo TAG synthesis in the liver,
and, therefore, additional sucrose as the part of the carbohydrate source will also be
important for plasma TAG development (Novelli, Diniz et al. 2007).

1.8

Dose response

Oats and mushrooms contain beta-glucan that is essential for lowering plasma lipid.
The FDA recommends consumption of 3g beta-glucan/day or equivalent with 75 g oat
or cereal as a functional food/day to prevent hypercholesterolemia and cardiovascular
disease in humans (FDA. 1996). There is no recommendation found for mushroom
beta-glucan as a functional food. Studies showed the range of mushroom powder
enriched diet for lowering plasma lipid in animal studies varied from 3% (wt:wt) (Mori,
Kobayashi et al. 2008) to 20% (wt:wt) (Talpur, Echard et al. 2002). Understanding
whether similar doses of oats and mushrooms are efficient in lowering plasma lipid and
preventing obesity will be important.
Using varied doses in the research is important for analysing the pattern of physiologic
response in different doses (Blakeslee 2011). Therefore, the most efficient doses of oats
and mushrooms as functional foods to be consumed for combating obesity can be
identified.
The main focus of this study is to compare the effect of an oat diet with a shiitake
mushroom diet in the prevention and treatment of obesity. Both of those functional
foods will be contrasted using comparable amounts of their beta-glucan. Since only oats
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has an established dose (3 g/day) for prevention of cardiovascular disease (FDA. 1996),
a 3 g/ day dose was used as a minimum dose in this project. Increasing doses will be
used to investigate the pattern of physiologic response and established dose response
effect. The magnitude of dose increase will be 3 times in each level. The same principle
will be used for the calculation of mushroom powder. This allows a relative equivalent
composition of beta-glucan derived from oats and mushrooms.

1.9

Summary

In summary, increasing BWG is normally caused by positive energy balance. One of the
causes of positive energy balance is an increase in the frequency of consumption of a
high fat diet. This study uses functional foods added into a high fat diet for prevention
and treatment of obesity given the increasing demand for functional foods in the
community. Oat and mushroom beta-glucan may possibly contribute to preventing and
treating obesity by decreasing hyperlipidaemia. The development of food viscosity is
possibly one of the mechanisms from beta-glucan for lowering plasma lipid (Lazaridou
and Biliaderis 2007). However, oats and mushrooms possibly have different roles and
mechanisms to manage obesity as beta-glucan impacts health in different ways
depending on the structure of the glycosidic bond as the structure of polysaccharide
(Lazaridou and Biliaderis 2007). Oat beta-glucan already has established doses for
lowering plasma cholesterol and preventing cardiovascular disease, however it is not
clear whether the same doses of Shiitake mushroom beta-glucan will produce a similar
plasma lipid lowering effect.

Dian Handayani

23

There are as yet insufficient reports concerning the effectiveness of oat and Shiitake
mushroom beta-glucan in preventing and treating obesity. Prevention and treatment of
the detrimental effects of a high-fat diet such as dyslipidaemia will be assessed and the
effectiveness of both sources of beta-glucan in prevention and treatment of obesity will
be compared. This research plan is depicted in Figure 2.1 and 2.3 (see Chapter 2 for
further information).
This research will be conducted to examine the hypothesis that mushrooms and oats
have similar beta-glucan effects and whether the different glycosidic bonds in betaglucan from oats and mushrooms use different mechanisms to reduce plasma lipid
levels and body weight. The mixed beta-glucan and eritadenine content of mushrooms
may have added value, especially the shiitake mushroom, and may act as a potential
functional food to manage obesity.
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1.10 Aims and Hypotheses
1.10.1 General aim and hypotheses
This project aims to study functional food rather than focusing on single isolated
molecules from the food. This study was to investigate the effect, underlying
mechanisms and dose response of oat and Shiitake mushroom powder as a functional
food enriched diet in rats fed a HFD.
It was hypothesized that these functional foods would have differential effects on
plasma lipid, fat mass deposition and BWG due to the different characteristics of the
beta-glucan molecule and the presence of eritadenine as another active nutrient in
mushrooms.

1.10.2

Specific Aims

The prevention study aims to investigate:
1. whether oat and Shiitake mushroom beta-glucan have different characteristics
and hence different effects and effective doses to prevent obesity in rats fed a
HFD (Chapter 3).
2. the effect of Shiitake mushrooms on food intake, energy efficiency ratio, plasma
lipid, and fat mass deposition in rats fed a HFD compared to rats fed HFD only
(Chapter 4).
3. the underlying mechanism of liver fat accumulation resulting from a Shiitake
mushroom enriched diet aimed at preventing obesity in rats fed a HFD (Chapter
5).
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The treatment study aims to investigate whether Shiitake mushrooms can treat existing
obesity in rats fed a HFD compared to rats fed a Shiitake mushroom enriched HFD
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CHAPTER 2.

2.1
2.1.1

GENERAL METHOD

Animal
Prevention Study

Seventy male Wistar rats at 9 weeks of age were purchased from the Animal Resource
Centre (ARC)-Perth, Western Australia. All experimental procedures were approved by
the Animal Ethics Committee of the University of Wollongong, AE 09/01. The animals
were housed two rats per cage in environmentally controlled conditions (temperature
22oC, light cycle from 06:00 to 18:00 hours and dark cycle from 18:00 to 06:00 hours)
and had ad libitum access to food and water. Rats were fed a commercial chow (rat and
mouse YS Feed, Young, NSW) in order to acclimatise to the new facility and
environment. The seventy rats were divided into seven groups (n=10) and fed ~ 50%
high-fat diet (HFD) with an additional nil, low, medium and high dose of oat powder or
Shiitake mushroom powder. The rat groups are: 1. HFD; 2. Low dose oat (LD-O); 3.
Medium dose oat (MD-O); 4. High dose oat (HD-O); 5. Low dose Shiitake mushroom
(LD-M); 6. Medium dose Shiitake mushroom (MD-M) and 7. High dose Shiitake
mushroom (HD-M). The low, medium and high doses of either oat or mushroom
contained beta-glucan that was comparable to 3, 9 and 27 g of the beta-glucan
requirement for humans, respectively. Ingredients of the seven diets are shown in Table
2.1, and their nutrient composition is shown in Table 2.2.
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Table 2.1 Ingredients (g per kilogram HFD) of prevention study

Food (g)
Carbohydrate
Cornstarch
Sucrose
Fat
Copha
Lard
Sunflower oil
Protein
Gelatine
Casein
Fibre
Bran
Other
Minerals
Vitamins
Oat
Mushroom
Water

LD-O

OAT
MD-O

HD-O

220
183

218
182

214
178

202
169

219
182

216
180

207
172

110
110
52

109
109
52

107
107
51

101
101
50

109
109
52

108
108
51

104
104
49

67
119

67
118

65
116

62
110

67
118

66
117

63
112

53

53

52

49

53

52

50

70
14

70
14
9

63
13
28

63
12
81

70
14

69
13

66
13

59

7
58

20
60

60
64

HD-O

MUSHROOM
LD-M
MD-M
HD-M

33
16
48
3
18.0

33
16
49
2
18.8

HFD

58

59

61

MUSHROOM
LD-M MD-M HD-M

Table 2.2 Nutrient composition of prevention study

(% From total energy)

HF-D

LD-O

OAT
MD-O

Carbohydrate
Protein
Fat
Fibre
Energy Density (kJ/g)

32
16
50
2
18.8

33
16
50
2
18.7

33
16
49
2
18.5

Nutrients

2.1.2

33
16
49
2
18.8

34
16
48
3
18.4

Treatment Study

Forty male Wistar rats at 9 weeks of age were purchased from the Animal Resource
Centre (ARC)-Perth, Western Australia. All experimental procedures when the rats first
arrived were the same as those in the prevention study. The forty rats were divided into
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four groups (n=10) and fed ~ 50% high-fat diet (HFD) with an additional nil, low,
medium and high dose of Shiitake mushroom powder ((1) HFD, (2) LD-M, (3) MD-M,
(4) HD-M. The low, medium and high doses of mushrooms contained beta-glucan that
was comparable to 9, 18 and 27 g of the beta-glucan requirement for humans,
respectively. Ingredients of the four diets are shown in Table 2.3, and their nutrient
composition is shown in Table 2.4.
Table 2.3 Ingredients per kilogram of treatment study
Food (g)
Carbohydrate
Cornstarch
Sucrose
Fat
Copha
Lard
Sunflower oil
Protein
Gelatine
Casein
Fibre
Bran
Other
Minerals
Vitamins
Mushroom
Water
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Mushroom
MD-M

HFD

LD-M

220
183

216
180

212
176

207
172

110
110
52

108
108
51

106
106
50

104
104
49

67
119

66
117

64
115

63
112

53

52

51

50

70
14

69
13
20
60

67
13
40
62

66
13
60
64

58

HD-M
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Table 2.4 Nutrient composition of treatment study
Food (g)
Carbohydrate
Protein
Fat
Fibre
Energy Density (kJ/g)

HFD
32
16
50
2
18.8

LD-M
33
16
49
2
18.8

Mushroom
MD-M
33
16
49
2
18.8

HD-M
34
16
48
3
18.4

The rat food in both the prevention and treatment studies was produced from semisynthetic material according to the recommendation of the American Institute of
Nutrition AIN-93 for rodents (Reeves 1997). Below is the list of food suppliers used in
the current study:
Corn starch (Goodman Fielder, NSW, Australia); Sucrose (Bella-vista, NSW,
Australia); Copha (Peerless Food, Victoria, Australia); Lard (Fonterra brand, Victoria,
Australia); Sunflower oil (Goodman Fielder, NSW, Australia); Gelatine, (Sunny Hills,
Qld, Australia); Casein (Fonterra Ltd, Auckland, New Zealand); Fibre (Nature,
Rosenberg, Germany); Mineral (MP Biomedical, Ohio, US); Vitamin (MP Biomedical,
Ohio, US); Oat : OatWell® 22% : Product code: 0003.01.0022 Crea Nutrition; Shiitake
mushroom powder (Shiitake mushroom, Shenzen Dashan, Food Stuff. Co. Ltd).
The experimental diets were prepared in the animal food preparation laboratory,
University of Wollongong. In brief, the dried material, except gelatine and sugar, were
mixed well in the mixer bowl. Half of the total water in Table 2.1 or 2.2 and 1 to 2
drops of food colouring was added to the sugar to be boiled in the microwave. In a
separate bowl, the gelatine, oil and the other half of the total water in Table 2.1 or 2.2
was mixed well and put in the microwave for 3 minutes. The mixed gelatine, water and
oil was added to the dried material slowly and mixed using the mixer on speed 1 for 30
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seconds. The dough was then mixed well by hand and put into the tray, flattened and
covered with plastic wrap. The dough was cut into ~ 2 x 2 x3 cm3 size and was ready to
give to the rats.

Figure 2.1
2.2

The samples of rat food; different colours show different doses

The design studies

The dietary intervention in the prevention study and the treatment study was carried out
for six weeks and 15 weeks respectively. The design studies for both the prevention and
treatment studies are shown in Fig 2.2 and Fig 2.3 respectively.
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Figure 2.2 Schematic diagram of Oat and Shiitake mushroom dietary intervention in
prevention study. HFD, high fat diet; LD-O, low dose oat; MD-O, medium dose oat;
HD-O, high dose oat; LD-M, low dose mushroom; MD-M, medium dose mushroom;
HD-M, high dose mushroom.

Figure 2.3
Schematic diagram of Shiitake mushroom dietary intervention in
treatment study. HFD, high fat diet; LD-M, low dose mushroom; MD-M, medium dose
mushroom; HD-M, high dose mushroom.
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2.3

Analysis: Shiitake mushroom beta-glucan content

The beta-glucan content from the Shiitake mushroom was analysed using a Megazyme
kit (K-YBGL 04/2008; Victoria, Australia) based on the protocol also supplied with the
kit. In brief, the mushroom sample was ground using a blender (Breville, Sydney,
Australia) and sieved into powder. The total glucan (α-glucan + β- glucan) and α-glucan
plus D-glucose content from the mushroom powder was analysed with a glucose
oxidase/peroxidase mixture from Megazyme (K-YBGL 04/2008; Victoria, Australia).
The absorbance of all solutions was read using an Elisa plate reader in 510 nm (power
wave X 340 – Biotech Instrument Inc). The total beta-glucan content was determined by
subtracting α-glucan from the total glucan. The calculation formula is downloadable
from

the

information

page

on

the

product

on

the

Megazyme

website

(www.megazyme.com).
2.4

Oats and Shiitake mushroom dose calculation

This study was to determine the effect of oats and mushrooms in preventing and treating
obesity. To obtain the effective dose for preventing dyslipidaemia and obesity in rats
fed a HFD, this current study used 3 different doses of oats and mushrooms, as both of
them contain beta-glucan that is reported to lower plasma lipid levels. As beta-glucan is
the main focus of analysis between oats and Shiitake mushrooms, this study used the
minimum amount of beta-glucan for human/day (3g/day) to prevent cardiovascular
disease, suggested by the FDA, for the low dose (FDA. 1996).
This study uses 3 different doses, low, medium and high. The medium dose of betaglucan content in oats and mushrooms was the amount of low dose beta-glucan
multiplied by 3 and the high dose was the medium dose multiplied by 3.Therefore the
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doses of oat and mushroom beta glucan are comparable with 3, 9 and 27g beta-glucan
/day for humans.
Calculation of the rat requirement of beta-glucan was based on the reference from
(Freireich 1966) which reported that the dose for rats is 7 times the human dose. If the
human requirement for beta-glucan-glucan is 3g beta-glucan/day, the estimated
requirement for a human with 70 kg body weight (BW) is 0.04g/kg bw. Doses for rats
are 7 times the human doses that were equivalent to 0.3g/kg body weight of rat.
Therefore, a rat with a 200g BW will need 0.06g beta-glucan/day which is comparable
to 3g beta-glucan/day for a 70 kg human.
This current study estimated total rat food/day ~30g (Nutrition., Nutrition. et al. 1995).
Total beta-glucan content is 22% (wt:wt) and 30% (wt:wt) from oats and mushrooms
respectively. As a result, in order to reach the 0.06 beta-glucan consumption in the low
dose diet, the total oat and mushroom powder that had to be added to the rat food was
0.9% (wt:wt) and 0.7% (wt:wt) respectively. After carrying out the calculation above,
Table 2.5 below shows the doses of oats and mushrooms that have been added to the rat
food.
Table 2.5 Additional oat and mushroom powder in rat food in prevention study
Doses

Oat Powder % (wt:wt)

Mushroom Powder % (wt:wt)

Low

0.9

0.7

Medium

2.7

2.0

High

8.1

6.0

As the research progressed, the prevention study showed that a Shiitake mushroom
enriched diet was more effective to prevent hypertriacylglycerol, increased BWG and
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increased fat pad masses compared to an oat enriched diet. Based on the results of the
prevention study, we only analysed the effect of Shiitake mushrooms in treating obesity.
We also considered that the results of the low dose mushroom diet in the prevention
study had not had significant effect on dyslipidaemia, BWG and fat pad masses,
therefore in the treatment study the dose was started higher in the low dose diet than in
the prevention study. Table 2.6 below shows the amount of additional mushrooms in the
HFD.

Table 2.6 Additional mushroom powders in rat food in treatment study

2.5

Doses

Mushroom Powder % (wt:wt)

Low

2.0

Medium

4.0

High

6.0

Food intake per rat, body weight and calculation of energy efficiency ratio

Food intake was measured every 24 hours by weighing the amount of total food (g)
provided to the rats and subtracting the remaining food (g) in the cage after 24 hours.
The result was divided by 2 to obtain food intake per rat. For both the prevention and
treatment studies, animals were weighed weekly throughout the intervention period.
The energy efficiency ratio (EER) was calculated by BWG per energy intake (g/kJ)
(Shin 2009).
2.6

Blood sampling collection from the tail vein.

Blood was sampled after the rats had fasted overnight. Blood samples were obtained
from the tail during the study for baseline information and from the heart after the end
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of study. Tail blood samples were collected based on the protocol from the National
Centre for the Replacement, Refinement and Reduction of Animals in Research
(NC3Rs). In brief, this method must be done by 2 people.1 person handles the rat when
the rat is in restraints and another person punctures the tail vein and collects the blood.
The rat is restrained with the tail poking out the end of the restraints or the rat is held
with a towel if the restraints are not available. The tail is warmed with warm water to
dilate the blood vessels prior to taking the sample (for around 1 minute with water at
38-39oC) and swabbed gently with a clean towel to clean the tail. The tail vein is located
on the left or right side by looking for the blue vein colour. The vein location that will
be punctured is swabbed with alcohol. The tail vein is punctured with a butterfly needle
(21G) and the blood drops to the wall of the tube. Approximately 0.5 – 2 ml of blood is
obtained and then the needle is slowly removed from the rat. The needle puncture is
pressed with cotton for around 4-5 seconds and then the rat is returned to the cage.
2.7

Plasma, tissue collection and body fat index (BFI) calculation

Rats were sacrificed via carbon dioxide asphyxiation before heart blood sampling. This
blood sampling was obtained by puncturing the right ventricle of the heart. All blood
sampled was collected in EDTA coated tubes and centrifuged at 3000 x rpm at 22oC for
25 minutes. Plasma was stored at -80oC until analysed.
The tissue samples collected included the liver and the fat pad masses which were
removed after blood sampling. The liver was weighed and placed into liquid nitrogen
before being stored at -80oC until analysed. The fat pad masses were dissected and
included white adipose tissue (WAT) comprised of visceral fat (epididymal, perirenal,
and omental fat) and subcutaneous fat (inguinal fat) and inter-scapular brown adipose
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tissue (BAT). All fat pad masses were individually weighed (g) using the standard
procedure (Han, Deng et al. 2008). The body fat index (BFI) was calculated as the total
amount of epididymal, perirenal, omental and inguinal fat deposits per 100g body
weight (Wang, Storlien et al. 2002).
2.8

Plasma Lipid analysis

Plasma triacylglycerol (TAG), total cholesterol (TC), high density lipoprotein (HDL)
and non esterified fatty acid (NEFA) were analysed using the Konelab® 20XT auto
analyser (see Chapters 3-5 for further details).
2.9

Liver analysis

The liver was analysed for TAG levels, liver histology, phosphathidylcholine (PC) and
phosphathidyl ethanolamine (PE) concentration (see Chapter 5 for further details).
2.10 Faecal analysis
Faecal waste was collected over a 24 hour period 3 x/week then weighed and analysed
for total fat content (see Chapter 3 for further details).
2.11 Statistical analysis
Statistical analysis was performed using SPSS software (version 17.0, SPSS Inc,
Chicago, IL, USA). One-way ANOVAs were used, followed by a post-hoc TukeyKramer significant differences test for multiple comparisons among the groups.
Differences were considered significant when p< 0.05. Multiple comparisons in Chapter
3 were analysed by two ways ANOVA. Dunnet‟s method was used to examine the
significance between the control group (HFD) and treatment groups. To examine the
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significant differences among treatments groups, the contrasts method was used. A p
value of 0.05 or less was considered significant. Statistical analysis was performed
using

SAS
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(SAS

Institute,

Cary,

NC,

USA).
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CHAPTER 3.

DIFFERENTIAL EFFECTS OF DIETS RICH IN
OAT AND SHIITAKE MUSHROOM WITH THE
FOCUS ON BETA GLUCAN AS THE ANTIOBESITY CONSTITUENT

3.1

Introduction

Oats and mushrooms have been found to be good sources of beta-glucan. An
enrichment diet of oats in a clinical study was not reported to lower plasma TAG levels
(Lovegrove, Clohessy et al. 2000; Maki, Davidson et al. 2003; Karmally, Montez et al.
2005; Queenan, Stewart et al. 2007) but lowered total plasma cholesterol (TC)
(Karmally, Montez et al. 2005; Queenan, Stewart et al. 2007). Limited human studies
(Schneider, Kressel et al. 2011) have shown the prevention of increased TAG plasma
levels using a mushroom enriched diet.
One of the mechanisms of oat beta-glucan in lowering plasma lipid is its capacity to
increase food viscosity (Beer, Arrigoni et al. 1995; Bae, Kim et al. 2009; Andersson,
Svedberga et al. 2010). By increasing viscosity of food in the lumen, beta-glucan was
reported to prevent and delay the absorption of nutrients. However, the viscosity of
beta-glucan is dependent on the molecular weight, molecular structure, and food matrix
(Lia, Halmans et al. 1995; Kerckhoffs, Hornstra et al. 2003; Bae, Kim et al. 2009).
While in nearly all of the reported research beta-glucan was found to be the main
component from oats with the potential to lower plasma lipid, in contrast, in research
using the Shiitake mushroom, not only was beta-glucan reported to lower plasma lipid,
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but other nutrient content such as eritadenine also lowered plasma lipids (Sugiyama,
Akachi et al. 1995; Sugiyama, Yamakawa et al. 1997; Shimada, Morita et al. 2003).
Another difference between oats and Shiitake mushrooms is the chemical structure of
their beta-glucan (Volman, Ramakers et al. 2008). Oat beta glucan consists of linear
unbranched β-(14)-D-glucopyranose units, which are separated every 2-3 units by a
single β-(13)-linked glucose unit (Volman, Ramakers et al. 2008). On the other hand,
mushroom beta-glucan is 13 β-linked glucopyranosyl with some 1,6 β-linked
branches (Volman, Ramakers et al. 2008).
Thus it can be predicted from the data that, when comparable amounts of beta-glucan
are consumed, Shiitake mushrooms will lower plasma lipid more effectively than oats.
These predictions are supported by the findings of an extraction of each component of
Shiitake mushrooms; for instance, polysaccharides and eritadenine lower plasma TAG
by 15% (Xu, HaiYan et al. 2008), and 39% (Takashima, Sato et al. 1974) respectively.
It has also been reported exoskeleton mushrooms which contain chitin-chitosan lower
plasma TAG lipid by 32% (Neyrinck, Bindels et al. 2009).
To the best of my knowledge, no data are available to examine the comparative effect of
oats and Shiitake mushrooms in preventing BWG in a similarly designed study. Such a
study would use equivalent dosages of beta-glucan for both the oat and mushroom
powders, and in addition, the same background high fat diet (HFD) would be given and
the same type of food matrix used to administer the oats and mushrooms.
The aims of this research were to 1) compare the effect of oat and mushroom powder to
prevent BWG; 2) determine the effective dose of oat and mushroom powder necessary
to prevent BWG and 3) determine the potential underlying mechanisms in preventing
BWG in rats fed a HFD.
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3.2
3.2.1

Materials and Methods
Animals and diet

Seventy male Wistar rats at 9 weeks of age were purchased from the Animal Resource
Centre (ARC)-Perth, Western Australia. All experimental procedures were approved by
the Animal Ethics Committee of the University of Wollongong, AE 09/01. The animals
were housed two rats per cage in environmentally controlled conditions (temperature
22oC, light cycle from 06:00 to 18:00 hours and dark cycle from 18:00 to 06:00 hours)
and had ad libitum access to food and water. Rats were fed a commercial chow (rat and
mouse YS Feed, Young, NSW) in order to acclimatise to the new facility and
environment. The seventy rats were divided into seven groups (n=10) and fed ~ 50%
HFD with additional nil, low, medium and high doses of oat powder and Shiitake
mushroom powder:(1) HFD, (2) low dose oat (LD-O), (3) medium dose oat (MD-O)
and (4) high dose oat (HD-O), (5) low dose Shiitake mushroom (LD-M), (6) medium
dose Shiitake mushroom (MD-M) (7) high dose Shiitake mushroom (HD-M). Oat
powder was from OatWell® Crea-nutrition and the Shiitake mushroom was from
Shenzen Dashan, Food Stuff. Co. Ltd, Shanghai that was imported by a local store in
Australia. The nutrient composition of the oats and mushrooms is shown in Table 3.1.
The low, medium and high doses of either oats or mushrooms contain beta-glucan that
is comparable to 3, 9 and 27g of the beta-glucan requirement for humans, respectively.
The composition of the seven diets is shown in Table 3.2.
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Table 3.1 Nutrient information of Oat Well® and Shiitake mushroom. Data per 100g on dry basis
Chemical Properties

Vitamins and Minerals

Fatty acids

Other specification
Molecular weight
Other Active components

Nutritive value
Protein (g)
Carbohydrate (g)
Total dietary fibre (g)
Beta-glucan soluble fibre (g)
Fat (g)
Energy Kcal or Kj
Sodium (Na) (mg)
Magnesium (Mg) (mg)
Calcium (Ca) (mg)
Potassium (K) (mg)
Iron (Fe) (mg)
Zinc (Zn) (mg)
Vitamin A (µg)
Vitamin B1(mg)
Vitamin B2 (mg)
Vitamin B6 (mg)
Vitamin B12 (µg)
Folic Acid (µg)
Vitamin C (mg)
Vitamin D (µg)
Vitamin E (delta-alpha-tocopherol)
Saturated FA (g)
Polyunsaturated FA (g)
Monounsaturated FA (g)
DA = Dalton = g/Mol
Chitin (%)
Eritadenine (%)
Chitosan

OatWell a
20
22
44
22
5
215/899
8
250
120
680
11
6
NA
0.3
NA
0.9
NA
44
NA
NA
0.1 mg
0.9
2.0
2.1

Shiitake mushroom
20 b
32.2 b
33.3 b
30 c
0.7 b
282/1178 b
30 d
1550 (Mattila, Konko et al. 2001)
500 (Mattila, Konko et al. 2001)
26.7 (Mattila, Konko et al. 2001)
33 (Mattila, Konko et al. 2001)
92 (Mattila, Konko et al. 2001)
NA
0.6 (Mattila, Konko et al. 2001)
1.8 (Mattila, Konko et al. 2001)
NA
0.8 (Mattila, Konko et al. 2001)
640 (Mattila, Konko et al. 2001)
25 (Mattila, Konko et al. 2001)
1 µg (Mattila, Konko et al. 2001)
NA
0.3 d
NA
NA

1,689,000(Beck, Tosh et al. 2009)
-

> 1,689,000
5.36 (Dikeman, Bauer et al. 2005)
0.3 – 0.63 (Enman, Rova et al. 2007)
-

a

Information based on product data sheet OatWell® 22%-Crea Nutrition; b Analysis by Grain Growers Limited (NSW-Australia) / Acc. No. 66; c
Analysis with beta-glucan-glucan KIT from Megazyme (K-YBGL 04/2008) (Victoria, Australia); d Information based on nutrient fact sheet from
Shiitake Mushroom Shenzhen Dashan Foodstuff Co. Ltd; NA: Not analysed
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Table 3.2 Composition of experimental diet
Group

Composition of Experimental diet
LDO

MDO

HDO

LDM

MDM

HDM

HFD

Carbohydrate (% from total energy)

33

33

33

33

33

34

32

Protein (% from total energy)

16

16

16

16

16

16

16

Fat (% from total energy)

49

49

48

49

49

48

50

Fibre (% from total energy)

2

2

3

2

2

3

2

0.9

2.7

8.1

-

-

-

-

-

-

-

0.7

2.1

6

-

Beta-glucan % (wt : wt)

0.2

0.6

1.8

0.2

0.6

1.8

-

Energy density (kJ/g)

18.7

18.6

18.0

18.8

18.8

18.4

18.8

Additional
Oat powder % (wt : wt)
Mushroom powder % (wt : wt)

The food was produced from a semi-synthetic material according to the
recommendation of “AIN93 diets for laboratory rodents”(Reeves 1997)

3.2.2

Body weight, food intake and fat pad masses

Animals were weighed weekly throughout the six week intervention period. Food intake
was measured every 24 hours by weighing the amount of total food (g) provided to the
rats and subtracting the remaining food (g) in the cage after 24 hours.
After completion of food intervention, rats were sacrificed via carbon dioxide
asphyxiation. The white adipose tissue (WAT) comprised of visceral fat (epididymal,
perirenal, and omental fat) and subcutaneous fat (inguinal fat) were then removed and
weighed.
3.2.3

Plasma lipid profile

Blood samples were obtained by puncturing the right ventricle of the heart and collected
in EDTA coated tubes and centrifuged at 3000 rpm at 22oC for 25 minutes. High
density lipoprotein (HDL) was isolated from plasma with dextran sulphate and
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magnesium chloride, based on a modified method from Sjoblom and Eklund (1989).
Total plasma cholesterol (TC), TAG, high density lipoprotein (HDL) and plasma Non
Esterified Fatty acid (NEFA) were measured using the Konelab® 20XT automatic
analyser. The TC, TAG and HDL were analysed with Infinity TM reagent from Thermo
Fisher Scientific (Auburn NSW, Australia) and plasma NEFA were analysed using a
highly specific enzymatic (Wako Chemical, Richmond, VA, USA).
3.2.4

Viscosity and molecular weight (MW) from oat and mushroom beta-glucan

3.2.4.1 Extraction of beta-glucan
Beta-glucans were extracted from commercial varieties of oats and Shiitake
mushrooms. Oats and Shiitake mushrooms were pulverized separately using a blender
(Breville, Sydney, Australia) and sieved through 355 µm mesh. Different concentrations
of oats and mushrooms (Table 3.6) were prepared by stirring a measured amount of
each powder in de-ionised water at 70oC for 30 minutes. The suspensions were then
centrifuged in a Sorvall RC-5B centrifuge (DuPont Company, Wilmington, Delaware,
USA) at 10,000 rpm for 30 minutes. The clear viscous supernatant solutions, containing
extracted beta-glucans, were collected for viscosity measurement.
3.2.4.2 Viscosity Measurement
The apparent viscosity of the extract was determined at a constant temperature of 37 oC,
to mimic human body temperature, using a DV III Rheometer (Brookfield, Middleboro,
Massachusetts, USA). A water-jacketed sample cup was employed to maintain a
constant sample temperature during the measurement. The speed of the rotating spindle
was increased and then decreased to the starting speed. The speeds were chosen so that
the torque exerted on the liquid was between the manufacturer‟s recommended ranges
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of 10 to 100%. At a particular speed, the viscosity was measured over the duration of 10
minutes. For the Shiitake mushroom beta-glucan, the minimum and maximum speeds
used were 35 rpm (shear rate of 263 s-1) and 55 rpm (shear rate of 413 s-1), respectively,
with an increment of 5 rpm. However, for the concentration 2 mg/ml, the maximum
speed possible before the torque exceeded 100% was 45 rpm. For the oat beta-glucan,
since there was a significant difference in viscosity with the change of concentration,
the range of speed that could be used (ensuring torque was between 10 – 100%) also
differed considerably. For 3 mg/ml, 8 mg/ml, and 25 mg/ml, the speeds used varied
from 20 to 55 rpm, 8 to 45 rpm, and 0.01 to 0.5 rpm, respectively.
3.2.4.3 Determination of molecular weight
Molecular weights of the oats and mushroom beta-glucans were determined by high
performance liquid chromatography (LC-20AT, Shimadzu, Kyoto, Japan) using a
refractive index detector (RID-10A, Shimadzu, Kyoto, Japan). Samples of 100 µL were
injected into a Waters Ultrahydrogel Linear 7.8 × 300mm size exclusion column
(Waters, Milford, MA, USA) that was maintained at 50oC during measurement. Deionised water (filtered through a 0.45 µm filter membrane) was the mobile phase, set to
flow at 0.7 mL/min. The run time per sample was 30 minutes. Polyethylene glycol
(PEG) with different molecular weights (1000, 3000, 4000, 6000, and 8000 dalton) and
pure beta-D glucan from Barley (Lot# BCBC4494V, Sigma Aldrich, Sydney, Australia)
with a molecular weight of 230,000 dalton were used as standards. The concentrations
of the standards were 15 mg/ml.

Oats and mushroom beta-glucan extracts, with

concentrations of 3 mg/ml and 2 mg/ml respectively (concentration shown in Table 3),
were run through the HPLC together with the standards.
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3.2.5

Faecal weight and fat content

In the last week of intervention, faecal samples were collected each day for 3 days from
all groups. The faecal samples from each cage (2 rats per cage) were collected, weighed
and frozen at -80oC until analysed for fat content. Fat content was analysed according to
the modified procedure described by (Kritchevsky and Tepper 2005). In brief, faeces
were dried in a freeze dryer for 48 h. The dried faecal samples were ground using a
mortar and pestle. Fat from the ground dried faeces was extracted by stirring in
chloroform-methanol 2:1, which was mixed well. The supernatant was recovered after
centrifugation at 3000 rpm for 5 minute at 22oC. The supernatant was then dried using a
stream of nitrogen. The dried fat was weighed using analytical balance (AND/HM-300,
Japan). The ratio of faecal fat to faecal weight was calculated as mg faecal fat per g
faecal weight.
3.2.6

Statistical analysis

Data were expressed as mean ± standard error of the mean (SEM). Data were analysed
by two ways ANOVA. Dunnet‟s method was used to examine the significance between
the control group (HFD) and the treatment groups. To examine the significance among
treatment groups, the contrasts method was used followed by a post hoc-LSD test. A p
value of 0.05 or less was considered significant. Statistical analysis was performed
using SAS 9.1 (SAS Institute, Cary, NC, USA) and SPSS software (version 17.0, SPSS
Inc, Chicago, IL, USA).
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3.3
3.3.1

Result
Oat and mushroom beta-glucan viscosity and molecular weight

In order to find the mechanisms for the different effects of the oat and mushroom
enrichment diets, this study characterized beta-glucan viscosity and molecular weight
from the oats and mushrooms. Generally, both the oat and Shiitake mushroom betaglucans showed shear thinning behavior where the viscosity decreased with higher
speed. At low speed, they also showed thixotropic behavior where the viscosity
decreased over time under constant shear rate. Due to the variety of speeds used (to
ensure that the torque exerted on the liquid was between the manufacturer‟s
recommended ranges), for comparison, the viscosity data at 45 rpm is presented (Table
3.3).
Table 3.3 Viscosities of oat and Shiitake mushroom beta-glucan solutions at different
concentrations.

Dose
Low dose

Oat
Concentration
Viscosity
(mg/ml)
(centipoises)
3
1.623 + 0.004

Shiitake Mushroom
Concentration
Viscosity
(mg/ml)
(centipoises)
2

0.812 + 0.003

Medium dose

8

6.425 + 0.018

6

1.056 + 0.019

High

25

5089 + 6.932

18

1.332 + 0.008

The values presented here were obtained at 45 rpm, except for high dose oat which was
obtained at 0.01rpm.
At this speed, the viscosity of the oat beta-glucan, at the concentrations studied in this
work was considerably higher than that of the mushroom. The viscosity of mushroom
beta-glucan even at the highest concentration (18 mg/ml) was lower than that of oat
beta-glucan at the lowest concentration (3 mg/ml), suggesting that viscosity is not the
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reason that mushroom beta-glucan is more effective to prevent weight gain and fat
accumulation than oat beta-glucan. The viscosity data of high dose beta-glucan in oat
solution (25 mg/ml) is shown separately because its value is 1000-fold higher (Table
3.3).
Size exclusion chromatography data showed that both the Shiitake mushroom and oat
extracts contained high molecular weight polymers, with those from Shiitake
mushrooms larger than those from oats (Fig 3.1).

Figure 3.1 High Performance Liquid Chromatography (HPLC) profiles of β-glucan
solutions extracted from oat and Shiitake mushroom and pure β D-glucan from barley.

3.3.2

Food intake, BWG and fat mass

This study compared the dose response effects of oat and mushroom enrichment diets
on the amount of food intake, body weight gain (BWG) and fat deposition of rats fed a

Dian Handayani

48

high-fat diet (HFD). Food intake did not differ among the seven groups of dietary
intervention (Table 3.4). The BWG was significantly affected by both diets and doses
(Table 3.4). The rats fed with the mushroom enrichment diet had lower BWG compared
with the oat enrichment diet (Fig. 3.1; p = 0.003). Furthermore, when comparing
between oat and mushroom powder there was no effect in the low dose (p = 0.743), but
significant effect in the medium dose (-16%, p = 0.040) and in the high dose (-34%, p =
0.002) groups (Fig. 3.2).
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Table 3.4 Food intake and BWG in rats fed experimental diets

Oat group

Mushroom group

Parameter

HFD
LD-O

MD-O

HD-O

LD-M

MD-M

HD-M

24 ± 1

26 ± 1

24 ± 1

24 ± 1

24 ± 1

23 ± 1

24 ± 1

Energy intake/rat/day (Kj)

454 ± 36

475 ± 51

431 ± 69

449 ± 27

448 ± 36

423 ± 44

458 ± 30

Body weight gain (g)

146 ± 13

179 ± 11#

139 ± 11

141 ± 9

150 ± 14

92 ± 8

129 ± 8

Food Intake/rat/day (g)

ANOVA

Dt; Ds

Values are mean ± SEM. Statistical analysis demonstrated # p<0.05 compared to HFD. ANOVA, analysis of variance (two way): Dt,
significant influence of diet (p<0.05); Ds, Significant influence of doses (p<0.05); HFD, High fat diet; LD-O, low dose oat; MD-O,
medium dose oat; HD-O, high dose oat: LD-M, low dose mushroom; MD-M, medium dose mushroom; HD-M, high dose mushroom.
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Figure 3.2 BWG of male Wistar rats after 6 week consumption of HFD enriched with
oat and mushroom. Data expressed as mean ± SEM. (*) significant (p = 0.003).
:
LD;
: MD;
: HD

The total fat deposition (epididymal + perirenal + omental + inguinal) was affected by
both diets and doses (Table 3.5). Rats fed a mushroom enrichment diet had significantly
lower total fat mass than the rats fed an oat enrichment diet (Fig. 3.3A, p = 0.001).
Furthermore, there was no effect on total fat mass when comparing the low dose (p =
0.515) and medium dose (p = 0.117) groups, but significant effects were seen in the
high dose (-41%, p = 0.015) group.
The WAT was affected by the diets and doses (Table 3.5). The rats fed a mushroom
enrichment diet had significantly lower WAT than the rats fed an oat enrichment diet
(Fig. 3.3B, p = 0.018). Furthermore, there were no significant effects in WAT when
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comparing the low dose and medium dose groups but a trend towards an effect in the
high dose (-32%, p = 0.072) group.
The inguinal fat mass was affected by the diets and doses (Table 3.4). The rats fed a
mushroom enrichment diet had significantly lower inguinal fat mass than the rats fed an
oat enrichment diet (Fig. 3.3C, p = 0.006). Furthermore, there were trends towards
effects in the low dose (- 30%, p = 0.082), medium dose (- 32%, p = 0.086) and high
dose (-47%, p = 0.078) groups.
No statistical differences were found in the amount of other fat mass (epididymal,
perirenal, omental, and visceral) deposition between rats fed a mushroom enriched diet
and rats fed an oat enriched diet.
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Table 3.5 Fat pad masses in rats fed experimental diets

Oat group

Mushroom group

Fat Masses (g)

HFD

ANOVA

8±1

11 ± 1

Dt

13 ± 1

9 ± 1#

14 ± 1

Dt x Ds

11 ± 1

11 ± 2

7±1

8±1

Dt x Ds

7±2

7±1

7±2

4±0

8±2

Dt ; Ds

40 ± 5

34 ± 4

37 ± 4

34 ± 4

23 ± 2

34 ± 2

Dt ; Ds

49 ± 5

51 ± 7

41 ± 5

44 ± 4

41 ± 4

28 ± 2

42 ± 3

Dt ; Ds

49 ± 5

52 ± 7

41± 5

44 ± 4

41 ± 4

28 ± 2

43 ± 3

Dt ; Ds

LD-O

MD-O

HD-O

LD-M

MD-M

HD-M

Epididymal (E)

13 ± 1

14 ± 2

12 ± 1

12 ± 1

13 ± 1

Perirenal (P)

16 ± 2

15 ± 2

13 ± 2

14 ± 2

Omental (O)

9±1

11 ± 1

11 ± 2

Inguinal

9±2

10 ± 2

Visceral (E+P+O)

38 ± 4

WAT
Total fat masses

Values are mean (± SEM). ANOVA, analysis of variance (two way): Dt, significant influence of diet (p < 0.05); Ds, Significant influence of
doses (p<0.05); Dt X Ds, significant interaction between doses and diet (p < 0.05); WAT, white adipose tissue; HFD, High fat diet; LD-O, low
dose oat; MD-O, medium dose oat; HD-O, high dose oat: LD-M, low dose mushroom; MD-M, medium dose mushroom; HD-M, high dose
mushroom.
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Figure 3.3 The total fat (A), white adipose tissue (WAT) (B) and inguinal fat (C) after 6
week‟s consumption of HFD enriched with oat and mushroom. Data expressed as mean
± SEM. (*) significant; A. (p= 0.001); B. (p= 0.017); C. (p= 0.006).
: LD;
:
MD;
: HD
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3.3.3

Plasma triacylglycerol, total cholesterol, high density lipoprotein, and non
esterified fatty acids

Plasma TAG levels were significantly affected by the diets and doses (Table 3.6). The
rats fed a mushroom enrichment diet had significantly lower plasma TAG levels than
the rats fed an oat enrichment diet (Fig. 3.4; p = 0.004). Furthermore, there were
significant effects on plasma TAG in rats fed a mushroom enrichment diet in the low (25%, p = 0.022), medium (-23%, p = 0.035), and high dose (- 27%, p = 0.011) groups
compared to rats on the oat enrichment diet. Plasma high density lipoprotein (HDL)
levels were significantly affected by diet (Table 3.6). The rats fed a mushroom
enrichment diet had significantly higher plasma HDL levels than the rats fed an oat
enrichment diet (p = 0.002). There was a trend towards higher HDL levels in high doses
of mushroom enrichment diet compared to the oat enrichment diet (+22%, p = 0.052).
There were no significant effects of diets and doses on plasma TC and non esterified
fatty acids (NEFA) (Table 3.6).
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Figure 3.4 The plasma TAG level after 6 week‟s consumption of HFD enriched with oat
and mushroom. Data expressed as mean ± SEM. (*) significant (p= 0.004).
: LD;
: MD;
: HD
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Table 3.6 Plasma lipid in rats fed experimental diets

Oat group

Mushroom group

Plasma Lipid

HFD

ANOVA

LD-O

MD-O

HD-O

LD-M

MD-M

HD-M

TC (mmol/L)

1.55 ± 0.06

1.66 ± 0.05

1.64 ± 0.08

1.56 ± 0.05

1.52 ± 0.06

1.54 ± 0.07

1.7 ± 0.07

TAG (mmol/L)

0.84 ± 0.06

0.83 ± 0.10

0.62± 0.06

0.63 ± 0.05

0.71 ± 0.08

0.39 ± 0.00#

0.85 ± 0.10

Dt, Ds

HDL (mmol/L)

0.96 ± 0.12

1.05 ± 0.03

1.03 ± 0.03

1.18 ± 0.17

1.06 ± 0.15

1.27 ± 0.06

1.19 ± 0.17

Dt

NEFA (mmol/L)

694 ± 46

723 ± 58

697 ± 51

709 ± 90

709 ± 63

723 ± 83

687 ± 63

Values are mean ± SEM. Statistical analysis demonstrated # p < 0.05 compared to HFD. ANOVA, analysis of variance (two way): Dt,
significant influence of diet (p < 0.05); Ds, Significant influence of doses (p < 0.05); TC, total cholesterol; TAG, Triacylglycerol; HDL,
high density lipoprotein; NEFA, non esterified fatty acid; HFD, High fat diet; LD-O, low dose oat; MD-O, medium dose oat; HD-O, high
dose oat: LD-M, low dose mushroom; MD-M, medium dose mushroom; HD-M, high dose mushroom.
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3.3.4

The weight of faeces and total lipid in faeces

Faecal weights were significantly affected by the diets and doses (Table 3.7). The only
diet that was statistically different to HFD was HD-O group showing a 24% reduction
in faecal weight (Table 3.7).
The faecal fat weight to faecal weight ratio was significantly affected by doses in rats
fed either mushroom or oat enrichment diets (Table 3.7). The faecal fat weight to faecal
weight ratio was 16% higher in HD-M enrichment diet compared to HD-O ( p = 0.026).
However, no differences in faecal fat weight to faecal weight ratio were found between
rats fed the same amount of low and medium doses of mushroom and oat enrichment
diets.
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Table 3.7 Faecal weight and fat faecal weight in rats fed experimental diets

Oat group

Mushroom group

Plasma Lipid

HFD

ANOVA

3.9 ± 0.3

4.1 ± 0

Dt;Ds;DtxDs

19 ± 0#

12 ± 0

Ds; Dt xDs

LD-O

MD-O

HD-O

LD-M

MD-M

HD-M

Faecal weight (g)/24 h

3.9 ± 0

3.5 ± 0.0

3.1 ± 0.2#

3.9 ± 0.1

3.7 ± 0.2

Faecal Fat (mg) / g faecal weight

12 ± 0

13 ± 0

16 ± 0#

12 ± 0

12 ± 0

Values are mean ± SEM. Statistical analysis demonstrated # p < 0.05 compared to HFD. ANOVA, analysis of variance (two way): Dt, significant
influence of diet (p<0.05); Ds, Significant influence of doses (p<0.05) ; Dt X Ds, significant interaction between doses and diet (p < 0.05);
HFD, High fat diet; LD-O, low dose oat; MD-O, medium dose oat; HD-O, high dose oat: LD-M, low dose mushroom; MD-M, medium dose
mushroom; HD-M, high dose mushroom. Faeces were collected once a day for 3 days from all groups in the last week of intervention.
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3.4

Discussion

The present study for the first time found that rats fed a HFD enriched with Shiitake
mushroom powder experienced lower BWG, fat deposition and plasma TAG, compared
with oat powder. To determine the beneficial effect of Shiitake mushrooms, dosage
must also be considered. This study showed that a high dose of mushroom enriched diet
led to greater exclusion of fat in the faeces compared to a high dose of oat enriched diet.
In general, animal studies that have been previously reported in the literature showed
that a mushroom enriched diet helped to prevent BWG (Kubo and Nanba 1996; Kim,
Kim et al. 2005; Neyrinck, Bindels et al. 2009; Noh, Lee et al. 2011). The data on BWG
prevention by mushrooms was dependent on the rat species (Kubo and Nanba 1996;
Talpur, Echard et al. 2002; Xu, HaiYan et al. 2008; Noh, Lee et al. 2011), dosages in
the diet and the variety of mushroom (Cheung 1998; Fukushima, Ohashi et al. 2001;
Talpur, Echard et al. 2002; Kim, Kim et al. 2005; Mori, Kobayashi et al. 2008; Noh,
Lee et al. 2011) . There are no reported clinical trials of a mushroom enriched diet to
prevent BWG in humans.
Few clinical studies of an oat enriched diet to prevent BWG have been reported, even
though an oat enrichment diet has been the subject of different studies with different
initial plasma lipid levels (Behall, Scholfield et al. 1997; Lovegrove, Clohessy et al.
2000; Kerckhoffs, Hornstra et al. 2003; Maki, Davidson et al. 2003; Karmally, Montez
et al. 2005; Queenan, Stewart et al. 2007), doses of additional oat (Lovegrove, Clohessy
et al. 2000; Karmally, Montez et al. 2005; Maki, Beiseigel et al. 2010), length of
treatment (Behall, Scholfield et al. 1997; Lovegrove, Clohessy et al. 2000; Kerckhoffs,
Hornstra et al. 2003; Queenan, Stewart et al. 2007) and food matrix (Behall, Scholfield
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et al. 1997; Kerckhoffs, Hornstra et al. 2003) all of which were unsuccessful in
preventing BWG. However a clinical study on oat enrichment diet reported decreased
BWG when oats were given concurrently with exercise and a low fat diet for 8 weeks
(Reyna-Villasmil, Bermu´ dez-Pirela et al. 2007). Furthermore, in an animal model, an
oat enriched diet showed decreased BWG when a 20% oat concentrate enriched diet had
43% beta-glucan content (Bae, Kim et al. 2009). However, 4% and 8% oat beta-glucan
enrichment to replace cellulose in hamsters fed a hypercholesterolemic diet did not
affect BWG (Delaney, Nicolosi et al. 2003). Hence the dose of oats is important and
also the possibility of exercise is also beneficial in preventing BWG.
There are very few studies that have investigated the effect of oat and mushroom
powder as part of a HFD on fat deposition. This current study showed that mushroom
powder (HD-M) was more effective than oat powder (HD-O) in lowering total fat mass
(35% vs. 5%), WAT (33% vs. 2%) and inguinal fat (50% vs. 13%). Similar results
were reported by (Kubo and Nanba 1996) where an additional 20% of Maitake
mushrooms in rats fed a cholesterol diet showed a 43% decrease in fat deposition. On
the other hand, no studies have reported the effect of an oat enrichment diet on fat
deposition.
It has been reported in the literature that mushroom and oat enriched diets have the
effect of lowering plasma TAG in humans and animals. For example, mushroom
enriched diets significantly lowered plasma TAG levels in animal studies (Takashima,
Sato et al. 1974; Kabir and Kimura 1989; Kubo and Nanba 1996; Talpur, Echard et al.
2002; Kim, Kim et al. 2005; Xu, HaiYan et al. 2008) and a human study (Schneider,
Kressel et al. 2011), however evidence from the oat enriched diets showed that more
than 20% of oats in the diet is necessary to lower TAG in rats (Andersson, Svedberga et
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al. 2010). Another study reported that an additional 20% oats with different molecular
weight (370,000 g/mol – 1,450,000 g/mol) in mice fed HFD had a significant effect on
lowering plasma TAG levels (Bae, Kim et al. 2009). However, in human studies,
additional oats in the diet had no effect on plasma TAG (Lia, Halmans et al. 1995;
Behall, Scholfield et al. 1997; Lovegrove, Clohessy et al. 2000; Kerckhoffs, Hornstra et
al. 2003; Karmally, Montez et al. 2005; Queenan, Stewart et al. 2007; Reyna-Villasmil,
Bermu´ dez-Pirela et al. 2007; Maki, Beiseigel et al. 2010).
It is well known that lowering plasma TAG will decrease NEFA circulation, so it will
decrease the source of fatty acid in adipose tissue through the process of adipogenesis
(Voshol, Rensen et al. 2009). It was also reported by Novelli, (Novelli, Diniz et al.
2007) that increased plasma TAG levels in rats fed HFD promotes fat deposition and
BWG.
This current study showed that a HD-M diet and a HD-O diet resulted in a 58% and
33%, respectively, increase in faecal fat excretion per faecal weight compared to a HFD.
Studies have found that a 40% oat enriched diet increased faecal cholesterol fourfold in
mice fed a high fat diet accompanied by

decreased plasma TC and TAG levels

(Andersson, Svedberga et al. 2010). A clinical study also reported that an oat diet in
healthy subjects increased fat in the faeces 57% more than a wheat bran diet (Chen,
Haack et al. 1998). Again, Cheung (1998) reported hamsters fed a HFD enriched with
Straw mushrooms significantly increased faecal sterol 81% more than hamsters fed the
control diet (HFD and cellulose) which was accompanied by a significant (36%) TC
lowering effect.
Some studies reported that the improvement in dyslipidaemia by beta-glucan was due to
viscosity (Beer, Arrigoni et al. 1995; Lia, Halmans et al. 1995; Kerckhoffs, Hornstra et
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al. 2003). Beta-glucan from both oats (Lund, Gee et al. 1989; Manthey, Hareland et al.
1999) and mushrooms (Guo, Williams et al. 2004) can slow down the digestion transit
time in the lower part of the small intestine and in the large intestine, therefore delaying
nutrient absorption. This study measured both oat and mushroom beta-glucan molecular
weight before these were added and mixed into the rat food. The results showed that
MW in Shiitake mushroom beta glucan was higher than the oat beta glucan used in this
study. However, it is uncertain whether the viscosity of oats or mushrooms alone would
be similar to the actual viscosity of rat food after it was added to oats or Shiitake
mushrooms. This is because in food enriched with oats and Shiitake mushrooms
viscosity was affected by the food preparation, such as food stored in a frozen state, and
the digestion process, that could decrease the MW of beta-glucan.
For instance, the freeze-thaw process will decrease MW by 40% and the digestion
process will decrease the MW by 100,000 Dalton (Brummer, Wood et al. 2006). In this
study, the rat food was frozen before being given to the rats. As the mushroom MW was
greater than oat MW, after the freeze–thaw process and digestion, the MW of the oats
was expected to remain < 1,000,000 Dalton and the MW of the mushrooms was
expected to remain > 1,000,000 Dalton. Although the correlation of MW and the effect
of viscosity were still doubtful, Tosh, Brummer et al (2008) reported that in order to
achieve the viscosity effect of beta-glucan, the MW should be > 1,000,000 Dalton.
Kerckhoffs, Hornstra et al (2003) also reported that a MW of beta-glucan < 1,200,000
Dalton could still lower plasma lipid if administered with a drink. Therefore, the
viscosity in oats and Shiitake mushrooms tested before they were added to the rat food
may not be able to explain the different effects of oat and Shiitake mushroom enriched
diets in lowering plasma lipid levels in vivo.
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Shiitake mushroom powder contains other active ingredients such as eritadenine and
chitin. Eritadenine may contribute to the effect by inhibiting plasma TAG derived
lipoprotein release from the liver (Yao and Vance 1988; Jacobs, Devlin et al. 2004). The
concentration of eritadenine is approximately 0.36% in Shiitake mushroom powder
(Enman, Rova et al. 2007). The HD-M diet used in this study contains ~200 mg
eritadenine/kg food. Sugiyama(Sugiyama, Akachi et al. 1995) reported that an
additional 50 mg eritadenine in choline deficient rats lowered plasma lipid by -68% and
-83% of plasma TC and TAG respectively.
Chitin is insoluble in water and grouped as functional fibre to lower blood lipids (Nwe
and Stevens 2002; Van Der Kamp, Asp et al. 2003). However, chitin needs to be
converted to chitosan to lower plasma lipid levels (Koide 1998). The process of
converting chitin to chitosan is by alkaline hydrolysis (45% NaOH, 100o) (Han, Kimura
et al. 1999), and this conversion is unlikely to have occurred in vivo; therefore, chitin is
unlikely to explain the reduction in plasma TAG in this study.
Accordingly, this result and references suggest the lowering of plasma TAG levels in
HD-M has possibly also been affected by eritadenine. This reasoning was supported by
data that showed that although the fat faecal exclusion of both HD-M and HD-O were
not significantly different the plasma TAG level, fat mass deposition and body weight
gain between HD-O and HD-M were significantly different. Therefore, other
mechanisms possibly promoted the lowering of plasma TAG levels in HD-M.
In summary, the mushroom diet is more effective than the oat diet as part of a HFD
because it reduces BWG, total fat mass, plasma TAG and increased fat faecal excretion.
The dosage required for these effects was the HD-M (60g Shiitake mushroom
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powder/Kg diet) with lower doses having minimal effects. One possible reason why
mushrooms were better than oats was the chemical structure of the mushroom. Food
enriched with Shiitake mushroom was more stable and retained viscosity effects after
the freeze-thaw process compared to food enriched with oats. In addition, Shiitake
mushrooms also contain another potential biological component, namely eritadenine
(discussed further in Chapter 5).
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CHAPTER 4.

DIETARY SHIITAKE MUSHROOM (LENTINUS
EDODES) PREVENTS FAT DEPOSITION AND
LOWERS TRYGLICERIDE IN RATS FED A
HIGH-FAT DIET

Published in Journal of Obesity

Handayani, D., J. Chen, et al. (2011) "Dietary Shiitake mushroom (Lentinus edodes)
prevents fat deposition and lowers triglyceride in rats fed a high-fat diet." Journal of
Obesity DOI: 10.1155/2011/258051.
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CHAPTER 5.

EFFECTS OF SHIITAKE MUSHROOM DIET ON
BODY WEIGHT GAIN AND LIVER WEIGHT IN
RATS FED A HIGH-FAT DIET

5.1

Introduction

Shiitake mushroom is grouped as a functional food that contains natural bioactive
substances such as beta-glucan and eritadenine (Henry 2010). The role of a Shiitake
mushroom enriched diet in lowering plasma lipid has been widely reported (Takashima,
Izumi et al. 1973; Kabir and Kimura 1989; Fukushima, Ohashi et al. 2001; Xu, HaiYan
et al. 2008). Recently the role of Shiitake mushroom in preventing BWG has been
reported but its mechanism remains largely unknown. The prior study identified that a
Shiitake mushroom enriched diet in rats fed a high fat diet (HFD) significantly lowered
plasma triacylglycerol (TAG) and fat deposition by -55% and -35% respectively,
compared to a HFD alone, although the food intake and calorie intake were not
significantly different (Handayani, Chen et al. 2011). It has also been identified, in
considering the doses of Shiitake mushroom, that a high dose mushroom (HD-M)
enriched diet significantly increased the ratio of faecal fat to faecal weight by +58%
more than HFD (See Chapter 3 for further details). The beta-glucan in the Shiitake
mushrooms was possibly assisting faecal fat exclusion through the effects of betaglucan viscosity.
Another biological component of Shiitake mushrooms, eritadenine, was reported to
have plasma lipid lowering effects including TAG and TC (Takashima, Sato et al. 1974;
Shimada, Morita et al. 2003). The lowering of plasma TAG levels in diets enriched with
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eritadenine derived from Shiitake mushrooms showed significantly increased liver TAG
(Sugiyama, Akachi et al. 1995).
The accumulation of TAG in the liver will contribute to development of hepatic
steatosis (Kleiner, Brunt et al. 2005). The mechanisms of eritadenine derived from
Shiitake mushroom in liver lipid metabolism were explained in Chapter 1.
It has been shown that Shiitake mushrooms contain eritadenine of approximately 3.86
mg/g of dried mushroom (Enman, Rova et al. 2007). Utilising this information, the
doses of Shiitake mushroom in this recent study contain eritadenine of around 27 mg/kg
diet, 77 mg/kg diet, and 232 mg/kg diet in LD-M, MD-M and HD-M respectively.
Therefore, the aims of this study were to 1) determine the liver weight, liver TAG, liver
fat histology, and liver phospholipid concentration;

2) determine the association

between dosages and liver fat content and 3) determine another underlying mechanism
of Shiitake mushrooms in preventing BWG in rats fed a HFD.
5.2
5.2.1

Materials and Methods
Animals and diet

Forty rats were divided into four groups (n=10) and fed ~50% high-fat diets with an
addition of Shiitake mushroom powder (g/kg diet); nil: high fat diet (HFD), 7: low dose
(LD-M), 20: medium dose (MD-M) or 60: high dose (HD-M). The dietary intervention
was carried out for six weeks as previously described (Handayani, Chen et al. 2011).
This study used Shiitake mushroom powder containing 30% β-glucan (w/w) analysed
with a Megazyme β-glucan Kit (K-YBGL 04/2008, Victoria, Australia). Each diet in the
treatment groups contained eritadenine (mg/kg diet) (±): 27, 77 and 232 in LD-M, MDM and HD-M respectively (Enman, Rova et al. 2007).
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5.2.2

Tissue collection and fractionation

At the end of the feeding period, rats were sacrificed via carbon dioxide asphyxiation.
The whole liver was quickly removed, weighed and placed in liquid nitrogen and then
stored at -80oC until analysed.
5.2.3

Liver crude fat weight and liver TAG analysis

Hepatic lipids were extracted by standard procedure from (Folch J, Lees M et al. 1957;
Mitchell, Turner et al. 2004) using ultrapure grade solvent, Methanol (MeOH, liquid
chromatography grade) from Merck (Darmstadt, Germany) and Chloroform (CHCl3,
HPLC grade) from Honeywell Burdick and Jackson (Muskegon, MI, USA). Analytic
grade butylated hydroxytoluene (BHT) was purchased from BDH laboratory (Foole,
BH15 1TD, England). Liver lipid was extracted with solvent chloroform-methanol (2:1
vol:vol) containing 0.01% butylated hydroxytoluene as antioxidant. Lipid extracted
from the liver was dried under nitrogen until it had constant weight. The liver crude fat
was weighed. After being re-dissolved in n-hexane, liver TAG was analysed based on
the method from (Kudo, Tamagawa et al. 2007; Villanueva, Yokoyama et al. 2011)
using the Konelab® 20XT automatic analyser with Infinity

TM

reagent from Thermo

Fisher Scientific (Auburn, NSW, Australia). In brief, the solvent was mixed well with
triton x (50uL solvent: 7.5 mg triton x). The solvent was dried under nitrogen for 24 H
to get to the detergent phase .which was then analysed using the Konelab® 20XT
automatic analyser after it was diluted with milliq water.
7.5 mg triton was added to every 50 µl solvent. Liver TAG was analysed based on the
method from (Kudo, Tamagawa et al. 2007; Villanueva, Yokoyama et al. 2011) using

Dian Handayani

77

the Konelab® 20XT automatic analyser with Infinity TM reagent from Thermo Fisher
Scientific (Auburn, NSW, Australia).
5.2.4

Liver Histology

This current study examined liver lipid accumulation using Oil Red O as described
previously (Anonymous ; Kudo, Tamagawa et al. 2007). In brief, frozen rat livers were
sliced in 10 µm sections with a cryostat (LEICA, Wetzlar, Germany) and fixed with ice
cold 10% formaline. The livers were air dried for 60 minutes and rinsed immediately in
3 changes of distilled water. After air drying for a few minutes, they were placed in a
solute propylene glycol solution for 5 minutes and stained with pre-warmed Oil Red O
solution (Oil Red O-SIGMA, St Louis, USA) for 10 minutes in 60ºC ovens. The slices
were differentiated in 85% propylene glycol solution for 5 mins then stained in Gill's or
Mayer's Hematoxylin and Eosin (Hematoxylin and Eosin solution, Sigma Chemical, St
Louis, USA) for 30 seconds. After washing thoroughly in running tap water for 3
minutes, cover slips were placed over the slices and mounted with glycerine jelly.
Histological images of Oil Red O-stained (ORO) liver sections were observed at 10 x
0.30 with a 0.17/A Fluotar, a 10 x 0.30, Leitz DMRB microscope and captured with a
Leica CCD digital camera, using a standard exposure for all photographs.
The histological features were identified as steatosis and ballooning. These were scored
using a previous method (Kleiner, Brunt et al. 2005). The steatosis grades have been
grouped into: < 5%, scored: 0; 5% - 33% scored 1; >33% - 66%, scored 2; > 66%,
scored 3. The ballooning classifications have been grouped into: 0, if there is no
ballooning degeneration; 1, if few balloon cells are obvious and 2, if there are many
cells/prominent ballooning.
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5.2.5

Liver Phospholipids Analysis

The liver was homogenized in four volumes (v/wt) on ice cold methanol: chloroform
(1:2 v/v) containing 0.01% BHT. Dinonadecanoyl phosphatidylcholine (PC 19:0/19:0)
and diheptadecanoyl phosphatidylethanolamine (PE 17:0/17:0) were added to the
homogenate as internal standards with final concentrations of 1 and 0.75 µmol/gram of
tissue respectively. Total lipids were extracted as described previously (Deeley,
Mitchell et al. 2008) and stored at -80 °C until analysis. Liver extracts were analysed
on a QTRAP 5500 (AB Sciex) combined with a Nanomate Trivera (Advion
Biosciences) robotic nanospray source. All samples were infused with a spray gas
pressure of 0.4 psi and voltage of 1.2kV. Lipid extracts were diluted 100-fold into
MeOH: CHCl3 (2:1 vol:vol) containing 7.5 mM ammonium acetate. PC lipids were
identified by precursor ion scanning for the m/z 184.1 product ion in positive mode. PE
lipids were identified by neutral loss scanning for a loss of 141 Th. in positive mode.
Collision energy was set at 55 eV and 30 eV respectively for precursor ion and neutral
loss experiments. 400 scans were summed for each experiment. Data was analysed with
LipidView (ABsciex) version 1.1, including de-isotoping, smoothing and isotope
correction. Absolute lipid concentrations were calculated using LipidView by
comparison to internal standards. Lipid concentrations were then exported to Excel
(Microsoft). The ratio of PC to PE was calculated as PC concentration per PE
concentration (mol/mol).
5.3

Statistical analysis

Data were presented as mean ± standard error of the mean (SEM). TAG liver data were
transformed to a square root value to achieve normality before significance testing.
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Statistical analysis was performed using SPSS software (version 17.0, SPSS Inc,
Chicago, IL, USA). One-way ANOVAs were used, followed by a post-hoc TukeyKramer significant differences test for multiple comparisons among the groups.
Differences were considered significant when P<0.05. A simple association between
two variables was calculated by Pearson's correlation coefficient.
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5.4
5.4.1

Result
Liver weight

Liver weights were not significantly different between the four diet groups, however,
the liver weight per 100g body weight was significantly different. Furthermore, this
study found that HD-M showed a significantly higher liver weight per 100g body
weight compared to LD-M (Table 5.1, +18%, p = 0.013) and MD-M (Table 5.1, +17%,
p = 0.015) respectively. However, there was no significant difference in liver weight per
100g body weight in HD-M compared to that in the HFD group.
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Table 5.1 Liver weight, triacylglycerol and phospholipid concentration in rats fed HFD enriched with Shiitake mushroom

Parameter

HFD

LD-M

MD-M

HD-M

ANOVA

19 ± 1

18 ± 1

17 ± 1

20 ± 1

NS

Liver weight/100 g body weight

3.9 ± 0.2a,b

3.6 ± 0.2b

3.5 ± 0.1b

4.1 ± 0.1a

0.008

Liver crude fat (g)

1.7 ± 0.4a,b

1.5 ± 0.2a

1.9 ± 0.5a,b

3.4 ± 0.7b

0.024

Liver Triacylglycerol (umol/g tissue)

45 ± 11a,b

21 ± 2a

19 ± 4a

69 ± 14b

0.001

34 ± 1

38 ± 2

39 ± 2

34 ± 2

NS

Phosphatidylethanolamine (PE) (nmol/mg)

9.7 ± 0.4a

10.6 ± 0.6a,b

11.9 ± 0.4b

11.8 ± 0.6a,b

0.026

Ratio PC/PE

3.5 ± 0.1b

3.5 ± 0.1b

3.3 ± 0.1a,b

2.9 ± 0.1a

0.001

Liver weight (g)

Liver phospholipid
Phosphatidylcholine (PC) (nmol/mg)

Abbreviations used: HFD, high fat diet; LD-M, low dose mushroom in HFD; MD-M, medium mushroom in HFD; HD-M, high dose
mushroom in HFD.
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5.4.2

Liver crude fat content

The liver crude fat was significantly different among the four diet groups (Fig 5.1; p =
0.024). Furthermore, this study found significantly higher levels of liver crude fat mass
in the HD-M group compared to the LD-M group (Table 5.1, +128%; p = 0.033) and a
trending higher compared to the HFD group (Table 5.1, +98%; p = 0.052), however the
HD-M group was not different compared to the MD-M group.

Figure 5.1 Liver crude fat mass was measured after 6 week‟s dietary intervention in
rats. Bars represent means ± standard errors. ab Means not sharing a common letter are
significantly different among groups at p < 0.05. Abbreviations used: see Table 5.1.

5.4.3

Liver histology

The HFD group and mushroom enriched diet groups were not significantly different in
hepatic steatosis using the histological scoring system (Table 5.2; p = 0.472). However,
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assessment of ballooning hepatosteatosis scoring revealed that the HD-M group had
significantly more cells ballooning than the HFD group, the LD-M and the MD-M
group (Fig. 5.2 Table 5.2; all p < 0.001). There was no significant difference in hepatic
ballooning in the HFD group compared to that in the LD-M and MD-M group.

Figure 5.2 Effect of mushroom enriched diet on lipid droplet deposition of hepatic
tissue by Oil red O staining. A: rat fed HFD; B: rat fed low dose mushroom; C : rat fed
medium dose; D: rat fed high dose mushroom
5.4.4

Liver triacylglycerol (TAG)

Liver TAG levels were significantly different among the four diet groups (Fig. 5.3, p =
0.001), in that the HD-M group had higher levels of liver TAG compared to LD-M
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(Table 5.3, +229%, p = 0.007) and MD-M (+257%, p = 0.001) groups. However the
HD-M group was not significantly different compared to the HFD group.

Figure 5.3 Liver triacylglycerol (TAG) levels were measured after 6 week‟s dietary
intervention in rats. Bars represent means ± standard errors. ab Means not sharing a
common letter are significantly different among groups at p < 0.05. Abbreviations used:
See Table 5.1.
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Table 5.2 Assessment of hepatic steatosis by histological scoring system and hepatic ballooning in rats fed HFD enriched with Shiitake
mushroom

Parameter
Hepatic Steatosis
Hepatic ballooning

HFD

LD-M

MD-M

HD-M

ANOVA

2.70 ± 0.20

2.83 ± 0.17

2.67 ± 0.21

3.00 ± 0.09

NS

0 ± 0a

1 ± 0a

0 ± 0a

2 ± 0b

0.000

Hepatic steatosis: 0, < 5%; 1, 5 – 33%; 2, >33% - 66%; 3, > 66%. Hepatic ballooning: 0, none; 1, few ballooning cells; 2, many
cells/prominent ballooning. Values are means ± SEM, n = 6. Within a row, values with different superscripts are significantly different,
P<0.05. Abbreviations used: See Table 5.1
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5.4.5

Liver phosphatidylcholine (PC) and phosphatidylethanolamine (PE)

The concentration of PC in the liver was not different among the four groups, while the
concentration of PE was significantly increased in the MD-M group compared to the
HFD group (Table 5.1; 22% p = 0.050). The HD-M group tended to have a higher PE
concentration than the HFD group (Table 5.1; 21%; p = 0.053), however the PE
concentration of the LD-M group was not significantly different compared to the HFD
group. The liver PC to PE ratio was significantly different among the groups (Fig. 5.4;
p=0.001). More specifically, a statistical difference in PC to PE ratio was found
between the HD-M group compared to the HFD (-16%; p = 0.001) and to the LD-M (15%; p = 0.005) group. However, no differences in PC to PE ratio were found in rats in
the HD-M and the MD-M group.
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Figure 5.4 Ratio PC/PE in liver was measured after 6 week‟s dietary intervention in
rats. Bars represent means ± standard errors. ab Means not sharing a common letter are
significantly different among groups at p < 0.05. Abbreviations used: See table 1

5.4.6

Correlation between the dosages of Shiitake mushroom and liver weight,
liver histology, liver TAG and liver PC: PE ratio

This study found that the amount of Shiitake mushroom added into the HFD was
positively correlated with liver TAG (R= 0.406; p = 0.017) and liver ballooning
histology (R= 0.878; p < 0.000). On the other hand, the dosages of Shiitake mushroom
showed a negative association with the ratio of PC to PE (Fig.6; R = -0.607; p <
0.0001). There was no statistical association between the amount of Shiitake mushroom
and liver weight (data not shown).
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Figure 5.5 Significant correlation was found between dosages of Shiitake mushroom
powder and the ratio of PC to PE.

Dian Handayani

89

5.5

Discussion

This study has shown that a HD-M enriched diet resulted in significantly increased
liver crude fat compared to a LD-M enriched diet and increased liver TAG compared to
a LD-M and MD-M enriched diet (Fig 5.1 and Fig 5.3 respectively) which is supported
by hepatic ballooning (Fig 5.2). This study showed a decreased PC/PE ratio due to the
increasing of PE in the HD-M group (Fig 5.4; Table 5.1). Furthermore, the ratio of PC
to PE was significantly correlated to the doses of Shiitake mushroom (Fig 5.5). One
potential underlying mechanism that explains the result could be the presence of
eritadenine in the Shiitake mushroom.
This current study showed no significant differences in liver weight, however when
compared per 100g BW, rats fed a HD-M diet showed a significantly higher liver
weight per 100g BW compared to rats fed a LD-M and MD-M diet (p = 0.008). In this
study the ratio of liver/body weight is higher in the HD-M group compared to the LDM and MD-M groups. This is due to the total fat mass and body weight being lower in
the HD-M group compared to the LD-M and MD-M groups while there were no
differences in liver weight between these three groups (see Chapter 4 for further
details). The effect of a mushroom enriched diet on liver weight also depended on the
source of mushroom and nutritional composition of the diet. For example, additional
Agaricus bisporus (Jeong, Jeong et al. 2010), straw mushroom (Cheung 1998) and
Maitake mushroom (Kubo and Nanba 1996) were not reported to increase liver weight.
A Shiitake mushroom enriched diet was reported not to have increased liver weight if it
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was given concurrently with a supplementation of 8 g choline chloride /kg diet
(Sugiyama, Akachi et al. 1995), however an additional 50 mg eritadenine derived from
Shiitake mushrooms/kg diet was reported to increase liver weight significantly (by
68%) in rats fed a choline deficiency diet for 2 weeks (Sugiyama, Akachi et al. 1995).
This current study and the Sugiyama study (Sugiyama, Akachi et al. 1995) suggested
that additional Shiitake mushroom in the diet will increase liver weight when given
without choline supplementation. Eritadenine from Shiitake mushrooms is possibly the
component inducing the increase in liver weight, because the high eritadenine level was
found only in Shiitake mushrooms (Saito, Yasumoto et al. 1975). Saito et al (1975)
identified the eritadenine content from Shiitake mushrooms as being ten times higher
compared to other edible mushrooms such as white button mushrooms. It was also
reported that other mushrooms such as Shimeji (Lyophyllum aggregatum), Jelly–ear
mushrooms (Auricularia auricula-judae), Enokitake (Flammulina velutipes) and
Nameko mushrooms (Pholiota nameko) contain no eritadenine (Saito, Yasumoto et al.
1975).
This current study showed increased liver TAG in the HD-M group compared to the
LD-M and MD-M group. Liver TAG in rats fed an HD-M was also 54% higher
compared to the rats fed a HFD but this did not reach statistical significance. Other
studies carried out to test the effect of enriched mushroom diets on liver TAG showed
varied results. For example, in an Agaricus bisporus powder enriched diet rats fed a
hypercholesterolemic diet had significantly lower liver TAG levels (Jeong, Jeong et al.
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2010). Again, an additional 20% Maitake mushroom powder in a hypercholesterolemic
diet significantly lowered liver TAG levels in SD rats (Kubo and Nanba 1997).
However, similar to the results on liver weight, additional eritadenine derived from
Shiitake mushrooms in rats showed different results in liver TAG. For example liver
TAG increased significantly by 776% when eritadenine derived from Shiitake
mushrooms was given concurrently with a choline deficiency diet (Sugiyama, Akachi
et al. 1995) but significantly lowered liver TAG by 28% when given concurrently with
an additional 6 g choline in the diet (Sugiyama, Yamakawa et al. 1997). Therefore, the
increase in liver TAG in this current study was correlated with increasing liver weight
that may have been affected by the role of eritadenine in the liver.
Normally, TAG is not stored in the liver and will be released as VLDL (Thompson
1990; Durrington 2007). The secretion of VLDL needs the presence of liver PC that has
a role in apoprotein B assembly with liver TAG and thus the liver TAG is released as
VLDL (Takashima, Sato et al. 1974; Yao and Vance 1988; Sugiyama, Akachi et al.
1995; Walkey, Yu et al. 1998; Shimada, Morita et al. 2003). It was suggested that liver
PC can be obtained from synthesis of PE via the Phosphatidylethanolamine Nmethyltransferase (PEMT) and CDP-choline pathways (Shimada, Morita et al. 2003;
Pynn, Henderson et al. 2011). A CDP-choline pathway was dependent on the source of
diet while the PEMT pathway for PC biosynthesis was not. The PC biosynthesis in the
PE N-methylation pathway only produces 30% of the total PC in the liver, therefore the
greatest PC biosynthesis was via the CDP-choline pathway (Watkins, Zhu et al. 2003).

Dian Handayani

92

Additional Shiitake mushrooms containing eritadenine in a diet with insufficient
choline was reported to decrease liver PC, because eritadenine prevents the production
of PC from the methylation of PE via PEMT. However, even though eritadenine
increased PEMT activity (Sugiyama, Akachi et al. 1995), increasing PEMT activity
did not automatically increase PC from the PEMT methylation pathway because the
PE-N methylation reaction not only needs enzyme mass but also a substrate such as Sadenocyl methionine (AdoMet). Eritadenine was reported to decrease PC from the
PEMT pathway by inhibiting S-adenocyl hydrolyse (Votruba, Morand et al. 1985).
The inhibition of S-adenocyl hydrolyse induces an increase of S-adenocyl
homocysteine (AdoHcy) and thus decreases the ratio of AdoMet to AdoHcy. The
decrease in this ratio inhibits PE-N methyltransferase to reduce the synthesis of PC
from PE; therefore it will decrease PC production in the liver (Sugiyama, Akachi et al.
1995). It was suggested that when Shiitake mushroom containing eritadenine was
added into a diet without sufficient choline chloride, the liver PC level will decrease
thus inhibiting the secretion of VLDL and then promote liver TAG accumulation and
decreased plasma TAG levels (Sugiyama, Akachi et al. 1995).
However, in this current study, there was no difference in liver PC concentration
between rats fed a HFD only and rats fed a Shiitake mushroom diet containing
eritadenine groups, even though choline chloride was not added into the diet of rats fed
Shiitake mushrooms containing eritadenine. It may have been expected that PC levels
would have been reduced in the Shiitake mushroom enriched diet group owing to the
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inhibition of the PE methylation pathway and low dietary choline levels limiting de
novo synthesis. A likely explanation for the lack of difference in liver PC concentration
is that liver choline is also supplied from PC and acetylcholine catabolism from other
tissues (Li and Vance 2008), which is used to maintain stable liver PC concentrations
(Robins 1975). Since the liver PC levels were not different among the groups while the
liver TAG in the HD-M group was significantly highest among the groups, the increase
of liver TAG in rats fed a HD-M diet needs further investigation.
This current study showed no significant difference in the presence of fat droplets and
hepatic steatosis between rats fed a HD-M and rats fed a HFD; however rats fed a HDM diet have higher hepatic ballooning compared to other groups. A previous study
reported that the high fat diet induced fatty liver (Wang, Wang et al. 2008), therefore
the presence of fatty liver in these groups seem to be induced by HFD. Thus, the
presence of eritadenine from the HD-M diet seems to have had adverse effects on the
hepatic steatosis by inducing hepatic ballooning. The possible mechanism for
development of hepatic ballooning in rats fed a HD-M is through the increase in liver
PE levels. This current study showed that the HD-M group significantly increased liver
PE levels compared to the HFD group. The increased PE results in a decrease in the PC
to PE ratio. The decreasing of PC to PE ratio induces increasing membrane
permeability in the liver (Li, Agellon et al. 2006). This current study found that the PC
to PE ratio in the HD-M group was the lowest ratio among the groups and a similar
result was found from other studies on rats fed an eritadenine enriched diet (Sugiyama,
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Akachi et al. 1995; Sugiyama, Yamakawa et al. 1997). Hepatic membrane permeability
will induce hepatic ballooning that is the result of cell damage typical of hepatic
steatosis (Li, Agellon et al. 2006). The increase in liver membrane permeability also
affects the infiltration of lymphocytes and other substances into the hepatocytes (Kmieć
2001; Bataller and Brenner 2005).
This study showed the positive association between liver TAG with dosages of Shiitake
mushrooms and liver ballooning with dosages of mushrooms. Because of this, the HDM diet is likely to have sufficient eritadenine levels to decrease the ratio of PC: PE.
Therefore, the presence of hepatic ballooning in this study could be concluded to have
been promoted by the decreasing of the PC to PE ratio.

In conclusion, this study revealed that rats fed a HD-M diet significantly increased liver
weight per 100g BW, and liver TAG, compared with rats fed a LD-M and MD-M but it
was not significantly different from rats fed a HFD. The increasing dose of Shiitake
mushroom showed an increase in hepatic ballooning, with the rats in the HD-M group
showing the highest incidence of hepatic ballooning. This study revealed that
eritadenine did not change the liver PC levels. Since the liver PC level among the
groups was stable, the inhibition of liver VLDL release cannot be seen to be another
mechanism to decrease plasma TAG levels. While the increasing of liver PE in a HDM diet affected the decreasing of the liver PC to PE ratio and was followed by hepatic
ballooning, further investigation will be warranted to achieve the benefit of Shiitake
mushrooms in combating obesity without promoting hepatic ballooning in the liver as a
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side effect. Therefore this current study needs to be repeated with additional choline
added to the diet to see if it can prevent hepatic steatosis and hepatic ballooning.
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CHAPTER 6.

TREATMENT

OF

INTERVENTION

OBESITY
WITH

BY

DIETARY
SHIITAKE

MUSHROOM IN RATS ON A HIGH-FAT DIET
6.1

Introduction

It has been widely reported that a mushroom enriched diet can reduce plasma lipids
(Kabir and Kimura 1989; Kubo and Nanba 1996; Cheung 1998; Fukushima, Nakano et
al. 2000; Fukushima, Ohashi et al. 2001; Mori, Kobayashi et al. 2008; Jeong, Jeong et
al. 2010; Schneider, Kressel et al. 2011). However, though with only limited data,
mushroom powder as part of a functional food to prevent increased BWG was also
reported (Kubo and Nanba 1996; Handayani, Chen et al. 2011). Another biological
component derived from mushroom, chitosan, was also reported as lowering body
weight (Neyrinck, Bindels et al. 2009), and beta-glucan extracted from Agaricus blazei
murill mushrooms was reported to decrease BWG in diabetic rats (Kim, Kim et al.
2005). There are various mechanisms involved in lowering plasma lipids, preventing
fat mass deposition and preventing BWG through the use of mushrooms in the diet.
The range includes inhibition of lipid absorption (Cheung 1998) and increasing fat
exclusion (Neyrinck, Bindels et al. 2009) and accumulation of fat in the liver was
demonstrated (see Chapter 5). Most of those studies were conducted as prevention
studies where the subjects were normal body weight before the commencement of the
study.
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Treatment is important to prevent the increasing prevalence of obesity. The National
Institute of Health guideline (National Institute of Health 2000) has suggested that
initially, obesity should be managed by a combination of diet modification, increased
physical activity and behaviour therapy (National Institute of Health 2000). Thus, using
enriched functional food in the diet to treat obesity needs further investigation.
A natural product can be classified as an obesity treatment product if it can: decrease
energy intake or decrease lipid absorption; increase energy expenditure or decrease
adipocyte differentiation and proliferation; or decrease lipogenesis and increase
lipolysis (Yun 2010). As human obesity has been reported to be more affected by
hyper caloric consumption than by genetic obesity (Van Heek, Compton et al. 1997),
preventing over consumption of food to decrease caloric intake will be beneficial in
treating obesity and /or decrease lipid absorption.
Obesity is a chronic disease that features hyperlipidemia and increased fat mass
deposition, namely adipose tissue that produces adipocytokines (Uysal et al. 1997;
Hotamisligil 1999; Hotamisligil 2006; Li et al. 2008). Adipocytokines are the key
source of systemic inflammatory response that has been reported to rise in obese
rodents (Xu, Barnes et al. 2003) and humans (Hotamisligil 2006; Cai, Cole et al. 2008
). The expanding adipocyte also produces monocyte chemoattractant protein-1 (MCP1). MCP-1 is a chemokine that promotes the migration of monocytes across the
endothelial wall thus developing low grade inflammation. This low grade inflammation
affects insulin action, lipid metabolism and endothelial dysfunction, which
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subsequently results in dyslipidaemia, metabolic syndrome and atherosclerosis (Lee
and Pratley 2005).
To the best of my knowledge, there has been no report of a Shiitake mushroom
enriched diet for treating obesity. In a previous investigation it was demonstrated that
Shiitake mushrooms were able to prevent the increase of plasma TAG, fat deposition
and BWG in normal rats fed a high fat diet (Handayani, Chen et al. 2011). Therefore,
this is the first study to test how Shiitake mushrooms can be used to treat obese rats.
The aims of the present study were to examine whether Shiitake mushroom could affect
energy intake, energy efficiency ratio, BWG, plasma lipid, plasma glucose, fat mass
deposition and circulating insulin, leptin and monocyte chemoattractant protein -1
(MCP-1) in obese rats fed a HFD.
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6.2
6.2.1

Materials and Methods
Animals and diet

Forty Wistar rats, at 9 weeks of age were obtained from the Animal Resource Centre
Perth, Western Australia, and were given one week acclimatization to their new
environment.

All experimental procedures were approved by the Animal Ethics

Committee of the University of Wollongong, AE 09/01. They were housed two per
cage in environmentally controlled conditions (temperature 22oC, light cycle from
06:00 to 18:00 hours and dark cycle from 18:00 to 06:00 hours) and had ad libitum
access to food and water. All rats were fed a standard laboratory non-purified diet (YS
Feeds Pty Ltd, Young, NSW, Australia) during the acclimatization period. At the end
of the first week, the rats were divided into four groups (n=10): high fat diet (HFD
group), low dose mushroom (LD-M group), medium dose mushroom (MD-M group)
and high dose mushroom (HD-M group). All of the groups had no significant
difference in initial body weight (g): 276 ± 5 (HFD); 287 ± 6 (LDM); 298 ± 8 (MD-M)
and 289 ± 6 (HD-M) (p=0.143) (n=10 in each group). All the rats were then switched to
a semi-synthetic high fat diet (HFD) with modified fat content based on the AIN-93 for
rodents (Reeves 1997) for 8 weeks to develop obese rats. The HFD consisted of the
material as previously described (Handayani, Chen et al. 2011). From week nine, the
control group (HFD) continued to be fed with HFD with no addition of Shiitake
mushroom powder; the LD-M, MD-M and HD-M groups were fed HFD with the
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addition of low (20 g/kg), medium (40 g/kg) or high (60 g/kg) doses of Shiitake
mushroom powder, respectively. This study used Shiitake mushroom powder
containing 30% β-glucan (w/w) analysed with a Megazyme β-glucan Kit. The dietary
intervention using Shiitake mushroom was carried out for seven weeks after 8 weeks‟
pre-treatment with HFD. A schematic diagram of dietary intervention is shown in Fig
2.3 in Chapter 2.
6.2.2

Experimental design

Animals were weighed weekly throughout the eight-week HFD intervention period,
that is, the pre-treatment period and the seven week treatment period. Food intake was
measured every 24 hours by weighing the amount of total food (g) provided to the rats
and subtracting the remaining food (g) in the cage after 24 hours. After the rats
consumed the HFD for eight weeks, blood samples were taken from the rats‟ tail vein
to determine the pre-treatment fasting plasma lipid and glucose concentration. After
seven weeks‟ treatment with Shiitake mushroom (at week 16), the rats were killed via
carbon dioxide asphyxiation. The collection of fat masses and blood samples and the
calculation of the energy efficiency ratio (EER) were also conducted as per the
previous study (Handayani, Chen et al. 2011).
6.2.3

Plasma lipid and plasma glucose analysis

The plasma total cholesterol (TC), triacylglycerol (TAG), high density lipoprotein
(HDL) and glucose were measured using the Konelab® 20XT with Infinity TM reagent
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from Thermo Fisher Scientific (Auburn NSW, Australia) (see Chapter 3 for further
details).
6.2.4

Plasma insulin, leptin and monocyte chemoattractant protein-1 (MCP-1)

The plasma insulin, leptin and MCP-1 were measured using luminex® xMap®
technology equipment (Luminex corporation, Texas, USA) with the commercial
Millipore rat adipokine multiplex kit (cat: #RADPK-81K). The luminex techniques
internally colour-code microspheres with precise concentration dye. The coloured bead
to be created was coated with specific capture antibody. The results of the bioassay
were quantified based on the fluorescent reporter signal using a high-speed digital–
signal processor. The adipokine multiplex kit was used according to the manufacturer‟s
instruction (Millipore, Billerica-MA-USA). Briefly, adipokine standard, assay buffer
and the plasma sample were put on a 96-well plate. An antibody-immobilized bead was
added to the well sample for capturing a test sample by the bead, followed by
additional biotinylated detection antibody. The mixture was then incubated with
Streptavidin–PE conjugate, the reporter molecule, to complete the reaction on the
surface of each microsphere. A high-speed digital signal processor identified each
individual microsphere and quantified the results of the bioassay based on the
fluorescent signal. The results for insulin, leptin and MCP-1 were expressed as pg/ml.
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6.2.5

Statistical analysis

Body weight, EER, energy intake, plasma lipids and plasma glucose were presented as
mean and standard errors. Treatment effectiveness is also presented as percent increase
or decrease. A paired student‟s t test was used to compare means pre and after
treatment in each group.

One-way ANOVAs were used, followed by a post-hoc

Tukey-Kramer significant differences test for multiple comparisons among the groups.
Statistical analysis was performed using SPSS software (version 17.0, SPSS Inc,
Chicago, IL, USA). Differences were considered significant when p< 0.05. A simple
association between two variables was calculated by Pearson's correlation coefficient.
6.3

Results

6.3.1

Body weight, Energy intake and Energy efficiency ratio (EER)

Each group significantly increased their mean body weight when comparing the pretreatment with after treatment period (Table 6.1; HFD, p < 0.0001; LDM, p < 0.0001;
MD-M, p < 0.0001; HD-M, p < 0.0001). Furthermore, this study found the increase in
body weight in mushroom treatment groups tended to be lower compared to HFD
(Table 6.2; HFD: +22%; LD-M: +20%; MD-M: +18%; HD-M: +17%; p = 0.100) but
did not reach statistical significant. This study demonstrated the decline in increased
body weight was correlated with the doses of Shiitake mushroom (R = -0.391; p =
0.013).
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The mean energy intake in HFD, LD-M and MD-M was significantly increased when
comparing the pre-treatment to the dietary intervention period (Table 6.1; HFD: +15%,
p < 0.0001; LDM: +17%, p < 0.0001 and MD-M: +7%, p < 0.0001). However, the
increase in mean energy intake was not significant in HD-M when comparing the pretreatment with the dietary intervention period (Table 6.1; +1%, p = 0.801). Furthermore
this study found the average energy intake in the pre-treatment period among the
groups was significantly different: the HD-M had the highest energy intake among the
groups (Table 6.1; p = 0.022). However, after treatment energy intake among the
groups was not significantly different (data not shown). Subsequently, the increase in
energy intake in the HD-M group was lowest among the groups (Table 6.2; +1%, p <
0.0001).
The pre-treatment EER in all experiment groups was significantly increased when
compared to EER after treatment (Table 6.1; p < 0.0001; LDM, p < 0.0001 and MD-M,
p <0.0001). In addition, there tended to be greater reduction of EER on the MD-M and
HD-M diet compared to HFD and LD-M (Table 6.2, p = 0.080).
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Table 6.1 Body weight, energy intake and energy efficiency ratio in HFD, LD-M, MDM and HD-M
Parameter

Group / treatment

HFD

Body weight (g)

EI (Kjoule)/24 H

EER (BWG/EI)

Pre-treatment1

472 ± 16

418 ± 12a,b

0.47 ± 0.02

After-treatment2

578 ± 25

479 ± 8

0.18 ± 0.02

0.000

0.000

0.000

Pre-treatment

470 ± 22

410 ± 12a

0.44 ± 0.03

After-treatment

564 ± 29

476 ± 6

0.16 ± 0.02

0.000

0.000

0.000

Pre-treatment

509 ± 17

432 ± 11a,b

0.49 ± 0.03

After-treatment

602 ± 22

461 ± 7

0.16 ± 0.02

0.000

0.000

0.000

Pre-treatment

490 ± 14

459 ± 10b

0.44 ± 0.02

After-treatment

574 ± 19

462 ± 2

0.14 ± 0.01

0.000

0.000

0.000

P Value
LD-M

P Value
MDM

P Value
HD-M

P value
1

Pre treatment: as long as induced HFD (wk 1 – wk 8)
After treatment with mushroom  blood sampling after treatment: after 7 weeks
treated with mushroom HD-M. Within a column, values with different superscript are
significantly different among the pre-treatments groups, p < 0.05. Data are mean ±
SEM; EER: Energy efficiency ratio (BWG/Energy intake (Kjoule)); EI: Energy Intake
(Kjoule) HFD, high fat diet; LD-M, low dose mushroom; MD-M, medium dose
mushroom; HD-M, high dose mushroom.
2
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Table 6.2 Mean treatment difference (%) pre treatment to after treatment of body
weight, energy intake and EER in HFD, LD-M and HD-M

Parameter
Body weight (g)
EI (Kjoule)/24 h
EER (BWG/EI)

Mean Treatment Difference (%)3

Anova

HFD

LD-M

MD-M

HD-M

↑ 22

↑ 20

↑ 18

↑ 17

c

a,b

a

b,c

↑ 15

↓ 62

↑ 17

↓ 61

↑7

↑1

↓ 67

↓ 68

NS
0.000
NS

3

Mean treatment difference (%): ((After treatment-pre-treatment/pre-treatment) X
100%). Within a row, values with different superscript are significantly different, p <
0.05. Abbreviations: see Table 6.1.

6.3.2

Correlation between doses of Shiitake mushroom and body weight gain

Comparing HFD to different doses of mushroom showed that body weight had no
significant differences (Table 6.2) although this study found that declining body weight
gain among the groups was negatively correlated with the doses of Shiitake mushroom
powder (Fig. 6.1).
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Figure 6.1 Correlation between body weight gain (%) and the doses of Shiitake
mushroom powder.

6.4

Plasma total cholesterol (TC), triacylglycerol (TAG), high density
lipoprotein (HDL) and glucose

This study found the mean of plasma TAG on HFD significantly increased when
comparing the pre-treatment with the after-treatment period (Table 6.3; +38%; p =
0.032). However, there were no significant differences in the plasma TAG levels within
the LD-M, MD-M and HD-M groups when comparing pre-treatment with aftertreatment. Furthermore, the change in plasma TAG levels in pre-treatment to after
treatment was significantly different among the groups (Table 6.4), in which only HDM showed a decline in plasma TAG level (Table 6.4; -3%; p = 0.046).
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This study found no significant differences in the plasma TC when comparing the pretreatment with after treatment within groups (Table 6.3).

Furthermore, the mean

treatment difference of plasma TC was also not significantly different among the
groups (Table 6.4). No significant differences were observed for HDL when comparing
pre-treatment with after treatment values (Table 6.2) and between groups (Table 6.3).
Plasma glucose tended to increase within all groups when comparing pre-treatment
with after treatment but only the HD-M group reached statistical significance (Table
6.3; +53%; p = 0.038), however the mean of plasma glucose was not significantly
different on HFD, LD-M and MD-M. Furthermore, no significant differences were
observed for mean treatment difference (%) pre-treatment to after-treatment of plasma
glucose (Table 6.4).

Dian Handayani

108

Table 6.3 Fasting plasma lipid and plasma glucose in HFD, LD-M, MD-M and HD-M
Parameter (mmol/L)

Group / treatment

HFD

TC

TAG

HDL

Glucose

Pre-treatment1

1.70 ± 0.06

0.58 ± 0.05

1.16 ± 0.07

8.49 ± 0.50

After-treatment2

1.77 ± 0.06

0.75 ± 0.06

1.11 ± 0.06

11.36 ± 1.32

NS

0.032

NS

NS

Pre-treatment

1.75 ± 0.08

0.77 ± 0.09

1.21 ± 0.05

7.33 ± 0.34

After-treatment

1.84 ± 0.11

0.87 ± 0.12

1.22 ± 0.10

10.71 ± 1.19

NS

NS

NS

NS

Pre-treatment

1.58 ± 0.05

0.70 ± 0.03

1.22 ± 0.08

7.94 ± 0.62

After-treatment

1.63 ± 0.05

0.75 ± 0.06

1.21 ± 0.08

10.38 ± 0.86

NS

NS

NS

NS

Pre-treatment

1.63 ± 0.09

0.73 ± 0.07

1.06 ± 0.04

6.69 ± 0.37

After-treatment

1.58 ± 0.08

0.67 ± 0.06

1.12 ± 0.04

10.21 ± 1.36

NS

NS

NS

0.038

P Value

LD-M

P Value

MDM

P Value

HD-M

P value
1

Pre treatment: as long as induced HFD (wk 1 – wk 8)
After treatment with mushroom  blood sampling after treatment: after 6 weeks was
treated with mushroom
Data are mean ± SEM; TC: Total cholesterol; TAG: Triacylglycerol; HDL: High
Density lipoprotein; NS: no significant difference. Other abbreviations: see Table 6.1.
2
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Table 6.4 Mean treatment difference (%) pre-treatment to after treatment of fasting
plasma lipid and glucose in HFD, LD-M, MD-M and HD-M
Parameter

Mean Treatment Difference (%)3

Anova

HFD

LD-M

MD-M

HD-M

↑4

↑5

↑4

↓2

NS

TAG (mmol/L)

↑ 38b

↑ 13ab

↑ 8ab

↓ 3a

0.046

HDL (mmol/L)

↓3

↑1

↑3

↑8

NS

Glucose (mmol/L)

↑36

↑ 53

↑21

↑55

NS

TC (mmol/L)

3

Mean treatment difference (%): ((After treatment-pre-treatment/pre-treatment) X
100%). Within a row, values with different superscript are significantly different, p <
0.05. Abbreviations: see Table 6.3.

6.4.1

Effect on body fat mass

This study found that all fat masses were not significantly different among the groups
(Table 6.5).

Dian Handayani

110

Table 6.5 Fat pad masses in HFD, LD-M, MD-M and HD-M after Shiitake mushroom
dietary treatment.
Fat masses (g)

Group

P Value

HFD

LD-M

MD-M

HD-M

Epididymal (E)

15 ± 2

12 ± 2

18 ± 2

16 ± 2

0.087

Perirenal (P)

23 ± 3

20 ± 2

23 ± 6

22 ± 3

0.760

Omental (O)

11 ± 2

9±2

11 ± 1

12 ± 1

0.371

Inguinal

8±1

6±1

8±1

8±1

0.486

Visceral (E+P+O)

50 ± 6

41 ± 4

52 ± 5

51± 5

0.499

WAT

53 ± 5

49 ± 5

59 ± 5

59 ± 6

0.571

BAT

0.7 ± 0

0.7 ± 0

0.6 ± 0

0.6 ± 0

0.319

Total fat mass

54 ± 5

50 ± 5

65 ± 7

59 ± 6

0.355

Groups abbreviations: see Table 6.1.
6.4.2

Effect on plasma insulin, leptin and MCP-1

This study showed that plasma insulin, plasma leptin and MCP-1 were not significantly
different among the control group (HFD) and treatment groups (Table 6.6).
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Table 6.6 Insulin, Leptin and Monocyte chemoattractant protein (MCP)-1 in HFD, LDM and HD-M after Shiitake mushroom dietary treatment
Group

Parameter

P Value

HFD

LD-M

HD-M

Insulin (pg/ml)

2,311 ± 417

3,210 ± 605

2,756 ± 497

0.467

Leptin (pg/ml)

14,678 ± 2,246

16,163 ± 2,894

16,774 ± 2,885

0.877

MCP-1 (pg/ml)

229 ± 37

212 ± 40

246 ± 62

0.852

Groups abbreviations: see Table 6.1
6.5

Correlation between fat pad masses and insulin or leptin

This study found that inguinal and omental fat were positively correlated with plasma
leptin (Fig. 6.3a and Fig. 6.3b respectively). Plasma insulin was also positively
correlated with plasma leptin. However both insulin and MCP-1 were not correlated
with fat mass deposition.
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a.

b.
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c.

Figure 6.2 Correlation between (a) insulin and leptin; (b) leptin and omental fat; (c)
leptin and inguinal fat.
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6.6

Discussion

This study demonstrated that obese rats fed a HFD for 8 weeks followed by treatment
with HD-M for 7 weeks showed the lowest energy intake and decline in plasma TAG
levels compared to other groups (Table 6.2). This study also found a negative
correlation between increasing body weight and the doses of Shiitake mushroom
(Fig.6.1). A positive correlation was found between plasma leptin and insulin. Plasma
leptin was also positively correlated with increased omental and inguinal fat mass
deposition. This is the first study to report the effect of Shiitake mushroom in treating
obesity in rats fed a HFD.
It appears that the lowest increase in energy intake in rats fed a HD-M was not affected
by additional Shiitake mushroom in the diet, since the energy intake in the pretreatment period of HD-M was significantly higher compared to other groups (Table
6.1). It was also shown that energy intake after treatment among the groups was not
significantly different. Therefore, it was demonstrated that dietary intervention with
Shiitake mushroom did not affect energy intake at all doses.
In this study, the rats were the same age and there was no difference in bodyweight
prior to treatment with Shiitake mushroom. As this study did not measure the rats‟
activity, that could possibly affect energy expenditure and energy intake, and therefore
the reason for higher energy intake in HD-M rats compared to other groups cannot be
explained.
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This current result relating to energy intake was consistent with a previous study in
which an additional 6% (wt:wt) Shiitake mushroom in an HFD diet did not decrease
energy intake in normal rats fed a mushroom enriched diet for 6 weeks (Handayani,
Chen et al. 2011). Another study showed the same result: administering 5% (wt:wt)
Shiitake mushroom in normal rats fed a hypercholesterolemic diet for 4 weeks did not
decrease energy intake (Fukushima, Ohashi et al. 2001). Again, an additional 20%
Maitake mushroom in normal SD rats fed a hypercholesterolemic diet showed no
lowering in energy intake. Furthermore, in a clinical study, a mushroom enrichment
diet did not decrease energy intake (Schneider, Kressel et al. 2011).
However, the lack of evidence on the use of dietary mushroom treatment for lowering
energy intake was reported by Jeong et al (Jeong, Jeong et al. 2010). The Agaricus
bisporus mushroom significantly decreased energy intake in diabetic rats by 9% (Jeong,
Jeong et al. 2010). The lowered energy intake in Jeong‟s study was affected by the
antiglycemic effect of Agaricus bisporus which promotes insulin secretion (Gray and
Flatt 1998; Jeong, Jeong et al. 2010). Moreover this antiglycemic effect improved a
diabetic condition by increased insulin sensitivity, leading to improvement in glucose
uptake from muscle and fat cells (Saltiel and Kahn 2001). The presence of glucose in
the circulation was followed by normal release of insulin which will increase the
feeling of fullness and suppress energy intake (Lavin, Wittert et al. 1996 ). Given this
issue, this current result suggested that the mushroom enriched diet did not decrease
energy intake in normal rats or obese rats. The lowered energy intake in the mushroom
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enrichment diet was more effective in diabetic rats and the mechanism possibly was
more correlated with the anti-diabetic effect of the mushroom.
This current study showed that after Shiitake mushroom dietary intervention, plasma
TAG levels declined in the HD-M group but not in other groups. The underlying
mechanism of Shiitake mushrooms to decrease plasma TAG levels was not analysed in
this current study. The HD-M group in this current study demonstrated that plasma
TAG levels decline by -3% from pre-treatment to after treatment. However, this decline
was not as great as in the HD-M group in the prevention study that reached -55%
(Handayani, Chen et al. 2011). The possible reason why the Shiitake mushroom did
not decrease plasma TAG levels in HD-M as much as in the prevention study described
earlier is because the HD-M was given after obesity had developed. It is well known
that in obesity there is an accumulation of excessive adipose tissue that is one of the
major risks for developing insulin resistance (Zeyda and Stulnig 2007). The decreasing
of insulin sensitivity in obesity disturbs the lipid and glucose metabolism such as that
which inhibits lipolysis from the fat cell, liver and muscle, inhibits glucose uptake from
muscle and fat cells and increases hepatic glucose (Saltiel and Kahn 2001). Those
conditions increase plasma lipid levels and high plasma glucose. Clearly, accumulation
of adipose tissue can affect lipid metabolism. This current study also used an HFD that
induced increased plasma lipid. Hypertriglyceridaemia in this current study was not
only affected by the HFD per se but was also affected by the metabolic disorder that
was induced by the increase in adipose tissue.
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No study has found that a mushroom enriched diet decreases plasma TAG in already
obese rats. However, lowered plasma TAG levels were reported when mushroom was
used as a dietary treatment on diabetic and spontaneous hypertensive rats. For example,
a mushroom enriched diet decreases the plasma TAG level by -48% in diabetic Sprague
Dawley (SD) rats fed Agaricus blazei murill for a 6 week intervention period (Kim,
Kim et al. 2005), by -44% in diabetic rats fed a normal diet with added Agaricus
bisporus for 3 weeks (Jeong, Jeong et al. 2010) and by -29%

on spontaneous

hypertensive rats fed a normal diet with added Shiitake mushroom for 8 weeks (Kabir
and Kimura 1989). Although the mechanism of Agaricus bisporus mushroom in
lowering plasma TAG in diabetic rats is unclear, one possible mechanism may be due
to lower food consumption (Jeong, Jeong et al. 2010). Again, it has been reported that
Agaricus bisporus contains lectin-like molecules that are reported to stimulate insulin
release from islet cells that could improve insulin insensitivity in diabetic rats (Ahmad,
Bansal et al. 1984). Subsequently, it will improve dyslipidaemia (Saltiel and Kahn
2001).
In view of this, the reason why Shiitake mushroom slightly decreases plasma TAG is
because of the accumulation of adipose tissue in obese rats that induces metabolic
disorder. This metabolic disorder affects dyslipidaemia. On the other hand, the HFD
given concurrently with Shiitake mushroom also provided a fat source in the
circulation, and therefore the Shiitake mushroom enriched diet could not significantly
decrease plasma TAG.
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No data were found related to use of a mushroom enriched diet to decrease plasma
cholesterol in obese animal and obese human studies. This current study revealed that
mushroom dietary intervention in obese rats did not significantly decrease plasma TC.
The reason why Shiitake mushroom cannot decrease plasma TC levels is possibly due
to the rat plasma content. Rat and human plasma have different lipid content. In
humans, the main cholesterol carrying lipoprotein is low density lipoprotein (LDL),
while in rats it is high density lipoprotein (HDL). Rats are more resistant to increased
LDL cholesterol elevation (Bauer 1996; Loeb and Quimbi 1999). The determination
by HPLC of rat plasma fed a normal diet showed that rats have higher plasma TAG
compared to plasma TC (Christie 1985). It has also been reported that in order to
increase plasma cholesterol levels, additional cholesterol and sodium cholate will be
needed (Kubo and Nanba 1996; Cheung 1998; Shimada, Morita et al. 2003; Jeong,
Jeong et al. 2010). In this current study, the HFD was not enriched with cholesterol
and sodium cholate to induce hypercholesterolemia. The total cholesterol plasma level
in this study was 1.72 mmol/L even after an induced HFD for 15 weeks. This value was
lower than other studies that used the same rat species, that is, 3.74 mmol/L after 14
days fed a high cholesterol diet (Shimada, Morita et al. 2003). Other species of rats
such as SD rats also showed higher plasma TC levels (6.5 mmol/L (Kubo and Nanba
1996) and 2.07 mmol/L (Takashima, Izumi et al. 1973)), compared to our study, after
being induced by a high cholesterol diet for 4 weeks and 12 weeks respectively. The
low level of TC plasma in this study is possibly the reason why this current study did
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not show significant effects of Shiitake mushroom in lowering plasma TC. This current
study was also consistent with the results in our preventive study (Handayani, Chen et
al. 2011) in which use of the same composition of HFD and Shiitake mushroom did not
decrease plasma cholesterol.
This current study showed a seven week dietary intervention in obese rats fed HFD had
no significant effect on HDL. Other animal studies using a mushroom enriched diet
demonstrated inconsistent results on plasma HDL levels. For example additional straw
mushroom in hamsters fed a hypercholesterolemic diet or additional Enokitake
mushroom in rats fed a normal diet significantly decreased plasma HDL by 36% and
14% respectively (Cheung 1998; Fukushima, Ohashi et al. 2001). In contrast, additional
Agaricus blazei murill mushroom in a normal diet showed increased plasma HDL in
diabetic SD rats (Kim, Kim et al. 2005). Other animal studies using additional Maitake
mushroom (Kubo and Nanba 1996), the mycelium part of straw mushrooms (Cheung
1998), Agaricus bisporus (Jeong, Jeong et al. 2010) or Shiitake mushroom (Xu, HaiYan
et al. 2008; Handayani, Chen et al. 2011) in the diet showed no significant effect on
rodent plasma HDL. One human study showed

similar results; additional oyster

mushrooms in the diet for 3 weeks did not significantly change the plasma HDL level
(Schneider, Kressel et al. 2011).
It has been suggested that rat plasma is predominantly HDL and resistant to dietinduced LDL elevation (Bauer 1996), possibly due to lack of enzyme cholesterol ester
transferase (CETP) that changes cholesterol ester from HDL to LDL and VLDL and
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tends to result in high HDL levels in rats (Loeb and Quimbi 1999). Rat HDL is also the
main transporter of plasma cholesterol (60-80% of total cholesterol) (Pisulewski,
Kopec et al. 2002). Therefore, dietary intervention to lower plasma TC should also
result in decreased plasma HDL. For example, the effect of a mushroom enriched diet
on hamsters fed a hypocholesterolaemic diet decreased plasma TC by -36% and
decreased plasma HDL by -36% (Cheung 1996). Another study showed an Enokitake
enriched diet in rats fed a high sucrose diet decreased plasma TC by -22% and
decreased plasma HDL by -14% (Fukushima, Ohashi et al. 2001). However, other
studies showed a different result; a decrease in liver TC by 42% was not followed by a
decrease in liver HDL (Kubo and Nanba 1996) and a decrease of -53% plasma TC was
not followed by decreased plasma HDL (Xu, HaiYan et al. 2008).
This current result was in agreement with other studies that showed plasma TC levels
and HDL levels were not affected by dietary intervention with mushrooms (Cheung
1998; Fukushima, Ohashi et al. 2001).
6.6.1

The link between fat mass deposition, plasma glucose, leptin, insulin and
MCP-1

This current study showed that treatment with a mushroom enriched diet in obese rats
did not decrease fat mass deposition. No treatment study has reported that a mushroom
enriched diet decreases fat mass deposition in obese rats. Again there has never been
any reported human study regarding the effect of mushrooms on total fat mass
deposition.
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Obesity was strongly correlated with the increase in adipose tissue as energy reserves
with TAG as the main form (Jackson and Ahima 2007). The adipose tissue was
associated with increased plasma leptin, insulin, and MCP-1 (Bedoui, Velkoska et al.
2005; Kadowaki, Yamauchi et al. 2006; Kanda, Tateya et al. 2006; Scherer 2006).
Although insulin and leptin levels increase in obesity, obesity is associated with a
blunted response to insulin and leptin, namely insulin resistance (Yamauchi, Kamon et
al. 2001) and leptin resistance (Jackson and Ahima 2007).
The presence of insulin and leptin resistance underlies the progression of obesity
including the elevated lipid level (Saltiel and Kahn 2001). This current study showed
no significant difference with respect to plasma insulin levels between obese rats fed
HFD and obese rats fed HFD with added mushroom. Other studies showed different
results in an animal model fed a mushroom enriched diet. For example, additional
Agaricus blazei murill for 6 weeks in diabetic SD rats significantly increased plasma
insulin by +87% compared to diabetic SD rats not fed an Agaricus blazei diet (Kim,
Kim et al. 2005). It means Agaricus blazei murill was effective for anti diabetic activity
by increasing the insulin levels. However, consumption of a diet with added chitosan
derived from mushrooms for 5 weeks decreased plasma insulin by -46% in normal
C57BL6/J mice with HFD-induced obesity (Neyrinck, Bindels et al. 2009). It means
additional chitosan from mushrooms is effective for lowering fat mass deposition, and
then reduces insulin resistance in rats fed an HFD. Again, another study on an Agaricus
campestris mushroom enriched diet showed that an additional ± 6% mushroom powder
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in the diabetic mice diet decreased plasma glucose by 51% compared to diabetic mice
fed without mushrooms, due to the insulin-like activity from the Agaricus campestris
mushroom (Gray and Flatt 1998). Those studies showed that the effect of mushroom
on plasma insulin and plasma glucose levels depends on the variety of mushroom, the
types of animal, such as animals in a diabetic state, and dietary content. To date, no
data have been reported on the dietary treatment effects of a mushroom enriched diet on
plasma insulin levels in obese rats.
Insulin resistance also affects glucose uptake from muscle and fat cells (Saltiel and
Kahn 2001). This metabolic disorder finally induces increased plasma glucose and
dyslipidaemia (Koopmans, Ohman et al. 1997; Lee and Pratley 2005). This current
study also showed that the changes of plasma glucose pre-treatment to after treatment
were not different among the groups. However, the level of plasma glucose in the HDM group was significantly increased after being treated with a Shiitake mushroom
enriched diet. A Shiitake mushroom enriched diet seems not to affect the increase in
plasma glucose because the rat plasma glucose in the pre-treatment diet already trended
to be lower than the other groups (p = 0.09). Therefore, it can be concluded that the
same amount of fat mass deposition among the groups had the same affect on plasma
insulin levels and possibly insulin action. Given these issues, the change in plasma
glucose was not significantly different among the groups.
This current study showed that the plasma leptin level was not significantly different
between obese rats fed HFD and those fed HFD enriched with Shiitake mushroom.
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The level of plasma leptin was related to fat mass deposition, for example, obese mice
fed HFD and an extract of Phellinus baumi (PBE) mushroom for 12 weeks showed
decreased plasma leptin levels compared to mice fed HFD only (Noh, Lee et al. 2011).
The PBE inhibited pancreatic lipase and thus reduced BWG by decreased plasma and
hepatic TAG. Neyrinck, Bindels et al

(2009) reported that a mushroom chitosan

enriched diet for 5 weeks significantly decreased plasma leptin by 69% in normal
C57BL6/J mice fed HFD compared to the controls. This mushroom chitosan diet also
reported significantly decreased fat mass deposition and prevention of BWG. No data
in human studies have reported that mushrooms can treat obesity and decrease plasma
leptin.
Leptin is known as an anorexigenic factor that inhibits appetite and leads to reduction
in body weight (Ippoliti, Liguori et al. 2008). However, increased leptin production in
obesity was followed by blunted leptin sensitivity, and thus induced leptin resistance
(Van Heek, Compton et al. 1997; Lin, Thomas et al. 2000). Accordingly, blunted leptin
sensitivity will inhibit its anorexigenic effect and therefore cannot prevent energy
intake, thus promoting obesity. This study showed that the plasma leptin levels were
positively correlated with omental and inguinal fat. Inguinal fat is part of subcutaneous
adipose tissue. A clinical study showed that subcutaneous and omental fats were
reported as the two fat masses that were strongly correlated with secretion of leptin as
they were the major areas of fat deposition (Van Harmelen, Reynisdottir et al. 1998). In
addition plasma insulin also positively correlated with plasma leptin. Given the issues,
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this current study was in agreement with other studies that reported that increased
adipose tissue will promote increased levels of plasma leptin and insulin and thus their
decreased sensitivity (Saltiel and Kahn 2001; Bedoui, Velkoska et al. 2005; Zeyda and
Stulnig 2007).
This current study showed that Shiitake mushrooms had no effect on plasma MCP-1. It
has been reported by another study that the increase in circulating MCP-1 was strongly
correlated with the increase in TNF-alpha in the circulation (Lee and Pratley 2005).
However, the plasma TNF-alpha in rats was not easily induced by HFD (Bedoui,
Velkoska et al. 2005) but predominantly occurred in severely obese genetic mutant rats
(Warne 2003). This study also showed that plasma TNF-alpha was not detectable (data
not shown). The plasma MCP-1 levels in this study were also not correlated with fat
mass deposition (data not shown). This current study showed that the levels of plasma
MCP-1 are 229, 212 and 246 pg/ml in the HFD, LD-M and HD-M groups respectively.
These data were lower than plasma MCP-1 levels from another study that measured
approximately 3,000,000 pg/ml in Zucker diabetic fatty rats (Jain, Velusamy et al.
2009). The high level of MCP-1 in Zucker diabetic fatty rats suggested that this rat was
genetically obese and in a diabetic state that was associated with hyperglycaemia and
the increase of MCP-1 (Jain, Velusamy et al. 2009).

In this study, MCP-1 data are

preliminary and require further investigation before any conclusions are drawn. This
study used Wistar rats as the animal model, and in this animal model it was not easy to
increase plasma MCP-1.
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In conclusion, the seven week Shiitake mushroom dietary intervention did not lower
energy intake. The slightly decreased plasma TAG levels in the HD-M group showed
that Shiitake mushroom was not strong enough to treat an increase in plasma TAG
levels. The plasma TAG levels in this current study were expected not only from the
HFD but also possibly from the existing adipocytokines induced metabolic disorder.
The seven week treatment with HD-M of obese rats fed an HFD was not sufficient to
correct BWG, fat mass deposition, plasma cholesterol, plasma HDL and circulating
leptin, insulin and MCP-1. The lack of efficacy of Shiitake mushroom maybe due to the
stage to which obesity has progressed. Changes in body weight, insulin sensitivity and
adiposity that occur in the early stages may be more susceptible to modulation by a
Shiitake mushroom diet. Continued HFD feeding may trigger irreversible late state
obesity resistant to treatment with a Shiitake mushroom diet.

Dian Handayani

126

CHAPTER 7.

CONCLUSIONS

AND

RECOMMENDATIONS

FOR FUTURE STUDY

7.1

Overall discussion

This research tested the effectiveness of oat and Shiitake mushroom enriched diets in
preventing obesity in rats fed a HFD. This study also investigated a Shiitake
mushroom enriched diet for treating obesity in obese rats fed an HFD.
In the prevention study, oats and Shiitake mushroom were compared in relation to
their effectiveness in preventing obesity. An exciting finding was that Shiitake
mushrooms prevented hyper triglyceridaemia plasma, fat mass deposition and body
weight gain more effectively than oats.
This thesis explored the potential mechanism of oats and Shiitake mushrooms to
prevent obesity. As this study concentrated on the ability of functional foods, oats and
Shiitake mushrooms, to prevent obesity, therefore the effect of the bioactive
components of oat and Shiitake mushroom powder that were added to rat food will be
shown. As both oats and Shiitake mushroom contain beta glucan, in the first study the
viscosity of oats and Shiitake mushroom were compared before it was mixed into the
rat food. The result showed that oats had higher viscosity than Shiitake mushrooms.
Viscosity is usually reported to be highly influenced by molecular weight (MW),
therefore this thesis also identified the MW of oats and Shiitake mushrooms. This
research found that Shiitake mushroom has a higher MW of beta glucan compared to
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oat beta-glucan; therefore it could be concluded that the high MW of Shiitake
mushroom beta glucan could not increase the viscosity in this project. The difference in
the chemical structure of oat and mushroom beta glucan may explain why Shiitake
mushroom was more effective. It has been reported that the main chemical structure of
Shiitake mushrooms is 1-3 glycosidic bonds and the main structure of oats is 1-4
glucopyranose units (Volman, Mensink et al. 2010). The 1-3 glycosidic bonds were
reported to be more stable in the freeze-thaw process (Lehtovaara and Gu 2011). Since
the freeze-thaw process is part of rat food preparation in this study, the presence of 1-3
glycosidic bonds as the main chemical structure may have allowed the Shiitake
mushroom beta glucan to remain viscous in the rat food. Moreover, the viscosity of rat
food enriched with oats and Shiitake mushroom is possibly different from the viscosity
of oats and Shiitake mushroom by themselves. The viscosity of oats and Shiitake
mushrooms as a single food cannot reflect the viscosity in rat food that has already had
oat or Shiitake mushroom added. As a result, this thesis revealed that rats fed HD-M
produce higher faecal fat exclusion compared to rats fed HD-O. The higher incidence
of faecal fat exclusion from Shiitake mushrooms affected inhibition of fat absorption
and thus decreased plasma TAG as the main plasma lipid in rats fed a HFD. This result
demonstrated faecal fat exclusion as one underlying mechanism of Shiitake mushrooms
in decreasing plasma TAG, fat mass deposition and the trend towards decreased BWG
is by.
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This is the first study that compared the use of oats and Shiitake mushroom beta glucan
in the prevention of obesity. Even though an oat enriched diet also increased faecal fat
exclusion when it was compared to a HFD, additional Shiitake mushroom showed a
greater increase in faecal fat exclusion than an oat enriched diet.
Since the Shiitake mushroom enriched diet has greater potential for preventing obesity,
this project subsequently concentrated on analysis of the effect of Shiitake mushrooms
compared to HFD only. This project demonstrated that a in a six week dietary
intervention with Shiitake mushrooms dose response had a negative correlation with
body weight, white adipose tissue, plasma TAG levels, body fat index and energy
efficiency ratio. In addition, this study suggested that there was a threshold effect in
terms of the amount of Shiitake mushroom intake for the prevention of weight gain in
rats fed a HFD. A high dose Shiitake mushroom, 60g/kg diet, was required to prevent
body weight gain in rats fed an HFD. On the other hand, a lower dose may not be
enough to prevent BWG.
Next, this research also indicated that Shiitake mushroom might achieve its dietary
intervention effects for decreasing plasma TAG and preventing BWG not only by
increased faecal fat exclusion but also can be multi-factorial including by the role
eritadenine which can lower plasma lipid (Takashima, Sato et al. 1974). This thesis has
highlighted the role of eritadenine as another underlying mechanism for Shiitake
mushroom to decrease plasma TAG, fat mass deposition and prevent body weight gain.
An interesting finding showed that eritadenine from Shiitake mushroom did not result
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in a decrease in liver PC that had previously been reported as mainly responsible for
inhibition of TAG lipoprotein released from the liver (Yao and Vance 1988; Walkey,
Yu et al. 1998). Even though the liver PC levels did not decrease, this thesis identified
that HD-M promoted liver TAG accumulation and produced hepatic ballooning. This
hepatic ballooning possibly resulted from the decreased ratio of PC to PE due to the
increased liver PE level. It was reported from another study that lowering the PC to PE
ratio could change membrane structure on the cell surface and cause a decrease in
membrane integrity (Li, Agellon et al. 2006). This decreasing membrane integrity
resulted in liver cell damage that has been reported to induce infiltration of
lymphocytes and other substances into hepatocytes (Kmieć 2001; Bataller and Brenner
2005). It is well known that lymphocyte size is 7000-8000 nm (Wheater, Burkitt et al.
1982) and that it is bigger than VLDL (43 nm) (Thompson 1990). Therefore, the
decrease in membrane integrity in this project probably allowed VLDL to freely diffuse
into the lining of the liver wall. Subsequently, the accumulation of VLDL in the liver
had adverse results in the form of hepatic steatosis and ultimately hepatic ballooning.
Indeed, this study indicates that hepatic ballooning and liver TAG accumulations were
positively correlated with the amount of Shiitake mushroom added into the HFD.
Finally, the increased influx of VLDL into the liver resulted in decreased plasma TAG
levels.
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Overall, this prevention study reveals that a Shiitake mushroom enriched diet was more
effective in preventing obesity than an oat enriched diet. An HD-M enriched diet
induced more faecal fat exclusion than an HD-O diet. Combined with the presence of
eritadenine in the HD-M, it significantly decreases plasma TAG levels in rats fed a
HFD without decreasing liver PC levels that could inhibit release of liver TAG. The
lowering of plasma TAG, was possibly affected by the lowered ratio of PC to PE that
induced increased membrane permeability. These results provide important information
on which to focus in future research to determine the optimal diet composition for
preventing obesity using Shiitake mushrooms. Inhibiting hepatic ballooning in an HDM diet might be critical in successfully preventing obesity using a Shiitake mushroom
enriched diet in an HFD.

In the treatment study, Shiitake mushrooms were used to treat obese rats fed an HFD
for seven weeks. Similar to the prevention study, only an HD-M diet was effective in
the treatment of obesity. However, the HD-M diet was not as effective in the treatment
of obesity as it was in the prevention of obesity. For example, in relation to plasma
TAG levels, the HD-M in the treatment study showed an insignificant decrease in
plasma TAG while other groups showed increased plasma TAG when they were
compared pre and post treatment with Shiitake mushroom. This slight decrease in
plasma TAG had no significant effect in preventing fat mass deposition. This is in
agreement with other studies that have reported that plasma TAG must be lowered by
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more than 24% to be able to decrease fat mass deposition (Kubo and Nanba 1996; Kim,
Kim et al. 2005; Handayani, Chen et al. 2011). Another significant effect of an HD-M
enriched diet in the treatment of obesity is that it showed the lowest increase in energy
intake pre-treatment to post treatment compared to other groups. Indeed, this study has
shown the decrease in energy intake apparently was not affected by the Shiitake
mushroom diet, because on baseline data, there was a trend for the energy intake of
HD-M to be higher compared to other groups. Again, the energy intake after treatment
among the groups was not significantly different. It has been identified from another
study that energy intake in rats treated with mushrooms was dependent on the rat‟s
condition (such as diabetic rats) and the component from mushroom that could
decrease energy intake (Jeong, Jeong et al. 2010).
This project has shown that existing obesity cannot be combated with HD-M dietary
intervention. A positive correlation has been found between plasma leptin and insulin
levels, and the plasma leptin level was significantly correlated with omental and
inguinal fat accumulation. It suggests that in this project, the existing obesity possibly
induced the metabolic disorder and promoted dyslipidaemia, but the presence of HD-M
dietary intervention given concurrently with an HFD, was not sufficient to decrease
plasma TAG and prevent obesity. Finally, this project showed that an HD-M diet
cannot be used to treat obesity in rats fed an HFD.
Based on the findings in the present thesis, recommendations for future research are
listed below.

Dian Handayani

132

7.2

Recommendations for further research
1. This current project analysed oat and Shiitake mushroom viscosity before its
addition into the rat food. Analysis of the viscosity of rat food with added oat
and Shiitake mushroom after food processing (including the freeze-thaw
process) will represent the real viscosity of the rat food enriched with oat or
Shiitake mushroom. It will confirm whether the difference in molecular
structure between oats and mushrooms has a different ability to retain beta
glucan viscosity. Since high food viscosity in the intestine will promote faecal
fat exclusion, it is important to study the relationship between viscosity from
food containing beta glucan and the amount of lipid and lipid content of faecal
exclusion.
2. In future, designing a study with the addition of sufficient choline in the
Shiitake mushroom enriched diet may be important to increase the ratio of PC
to PE to inhibit the hepatic ballooning side effect in a Shiitake mushroom
enriched diet. This study indicated that the addition of choline chloride in the
diet may prevent the loss of hepatic membrane integrity in an HD-M diet. The
choline chloride will increase liver PC thus increasing the ratio of PC to PE.
Lowering permeability of the liver membranes will possibly decrease the influx
of plasma VLDL to the liver and thus inhibit the production of hepatic
ballooning.
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3. An analysis of the LDL receptor-related protein (LRP) in the liver should be
undertaken, as this member of the LDL receptor gene family is heavily
expressed in the liver, and mediates removal of VLDL remnants (IDL) (Kim
and Vaziri 2005). After designing an experiment with additional choline in the
diet, it can be assumed that liver membrane permeability will be restored to
normal and stabilised. Accordingly, the uptake of plasma VLDL to the liver will
be managed from the receptor (LRP) activation.
4. Lipase activity could be considered a marker of non metabolite lipid. Analysis
of this activity will support understanding of the underlying mechanism of
Shiitake mushroom in increasing faecal fat exclusion.
5. The Shiitake mushroom enriched diet has shown no significant effect on
combating existing obesity in rats fed a HFD. It has been reported that the
existing fat mass deposition in rats fed an HFD makes weight loss using a
Shiitake mushroom enriched diet difficult as it is hard to maintain lowered body
weight gain. Therefore, additional Shiitake mushrooms in an HFD for treatment
of existing obesity did not warrant further investigation in combating obesity.

In summary, as the prevalence of obesity escalates on a global scale and community
awareness of the potential role of functional food also rapidly increases, it is important
to provide scientific evidence on the effect of functional foods in the prevention and
treatment of obesity to stop this obesity epidemic. The current project has shown that
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Shiitake mushroom is effective at a high dosage to prevent obesity by lowering plasma
TAG, lowering fat mass deposition and the trend towards preventing increased body
weight gain without changing energy intake. However, hepatic ballooning as a side
effect of an HD-M diet must be considered. This project also revealed that a
combination of HFD and Shiitake mushroom were not powerful enough to combat
existing obesity. These results have significant practical implications as they provide
potential evidence of the role of functional food as a future agent in the prevention of
obesity.

In conclusion, a Shiitake mushroom enriched diet was more effective than an oat
enriched diet in preventing body weight gain; however there are side effects that
warrant further investigation. In addition, Shiitake mushroom was not effective in
treatment of existing obesity
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